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Abstract:
Nowadays, more and more high-throughput genomic data sets are publicly available; there- 
fore, performing meta-analysis to combine results from independent studies becomes an 
essential approach to increase the statistical power, for example, in the detection of differen- 
tially expressed genes in microarray studies. In addition to meta-analysis, researchers also 
incorporate pathway or clinical information from external databases to perform integrative 
analysis. In this thesis, I will present three projects which encompass three types of integra- 
tive analysis. First, we perform a comprehensive comparative study to evaluate 12 microarray 
meta-analysis methods in simulation studies and real examples by using four quantitative 
criteria: detection capability, biological association, stability and robustness, and we pro- 
pose a practical guideline for practitioners to choose the most appropriate meta-analysis 
method in real applications. Second, we develop a meta-clustering method to construct co- 
expressed modules from 11 major depressive disorder transcriptome datasets, incorporated 
with GWAS and pathway information from external databases. Third, we propose a com- 
putationally feasible algorithm to call genotypes with higher accuracy by considering family 
information from next generation sequencing data for two purposes: (1) to propose a new 
genotype calling algorithm for complex families, and (2) to extend our algorithm to incor- 
porate external reference panels to analyze family-based sequence data with a small sample
v
size. In conclusion, we develop several integrative methods for omics data analysis and the
result improves public health significance for biomarker detection in biomedical research and
provides insights to help understand the underlying disease mechanisms.
vi
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1.0 INTRODUCTION
1.1 DEVELOPMENT OF OMICS TECHNOLOGY
RNA microarray is an important technology for studying gene expression, which can quan-
tify the amount of mRNA transcripts present in a collection of cells, and has been widely
used to identify differential expressed (DE) genes in biomedical research. Many microar-
ray platforms were commonly used such as dual- label cDNA; oligonucleotide platforms;
Affymetrix GeneChip or Illumina BeadChip. These high-throughput technologies provide
us an opportunity to measure thousands of genes and can help identify disease patients or
identify candidate genes that contribute to tumor progression, and also improve in cancer
diagnostic and prognosis. However, limitations of microarray technology are the quality and
amount of RNA, and can only provides gene-based information.
In the past decade, Genome-Wide Association Studies (GWAS) have generated a consid-
erable amount of gene- and disease-related information. GWAS usually test for the associa-
tion between genotype and phenotype on hundreds of thousands to millions SNPs simulta-
neously and provides unbiased of large scale investigation of DNA structural (SNP and other
variants) changes. GWAS have been successfully identified thousands of associated SNPs for
many common diseases [Hindorff et al., 2009], but heterogeneity and various sources of noise
have limited the discovery of disease mechanisms. In the beginning of GWAS in the past
era, many data sets have small sample sizes due to high costs, however, GWAS typically has
small effect sizes, and such disease-related loci can be detected only by very large sample
sizes, and most of GWAS do not replicate their finding in subsequent studies.
Next Generation Sequencing (NGS) is the most advanced technology, which can be used
for systematically searching the rare variants and help people discover the disease mecha-
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nisms. In 2010, the 1,000 Genome Project has generated publicly available database and
provided a deep characterization of human genome sequence for people to understand the re-
lationship between genotype and phenotype, which is the central goal in biomedical research
[Abecasis et al., 2010]. Unlike GWAS (generate one genotype at each locus), NGS technology
generated millions of short segments of sequence “reads” (25 - 250 base), then we need to
strongly rely on comprehensive computational analysis to assemble millions of “short-reads”
into full sequence. Over 95% of variants in genome regions have allele frequency of 1% or
higher were accessible in NGS technology is the major advantage, however, short reads make
assembly hard, and does not allow the assessment of copy number accurately. In addition,
the cost of NGS data set still high and not affordable for many small labs.
1.2 INFORMATION INTEGRATION
In the past decade, more and more biological high-throughput genomic data sets were pub-
licly available, especially for transcriptomic study of microarray experiments. Combining
results from independent studies is an essential way to increase the statistical power to de-
tect differential expressed (DE) genes because the signal from single study is weak (due to
limited sample sizes or small effect sizes), especially for complex diseases such as major de-
pressive disorder (MDD); hypertension or Diabetes. Most of published papers of integrative
analysis were meta-analysis for DE gene in microarray study. In addition to meta-analysis,
incorporating external database such as GWAS or pathways, and integration of clinical data
were also alternative ways of integrative analysis. In this section, we will briefly introduce
three ways of integrative analysis which are relevant to three topics of my dissertation: (1)ge-
nomic meta-analysis; (2)integration of external database and (3)integration of family-based
data.
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1.2.1 “Horizontal” and “Vertical” genomic meta-analysis
In the comprehensive literature review for microarray meta-analysis proposed by Tseng et al.
[2012], the genomic information integration from transcriptomic studies can be combined
“horizontally” (Figure 1(A): combines different sample cohorts for the same molecular event)
or “vertically” (Figure 1(B): combines different molecular events usually in the same sample
cohort, for example, transcriptome profile, genotypes, DNA copy number variation, methy-
lation, microRNA, proteome and phenome. Such as The Cancer Genome Atlas (TCGA;
http://cancergenome.nih.gov/)). In addition to increase the statistical power, genomic meta-
analysis can also provides robust and accurate validation across independent studies, and
the result can guide future experiments. In Tseng et al. [2012], they also indicated that
many meta-analysis methods have been proposed and used in published applications, but
the hypothesis behind the analysis needs more attention. In chapter 2, we performed a
comprehensive comparative study of microarray meta-analysis method.
1.2.2 Integration of external database
There were many external databases of integration analysis were publicly available and can
be used for genomic research. Unlike microarray study, we are unable to get whole data sets
or SNPs list from most of GWAS publications to replicate their results, however, there is a
database called GWAS catalog collected a list of SNPs/genes reported by GWAS publications
[Hindorff et al., 2009], this database contains many entries of disease- or trait-associated
SNPs with p-values less than 10−5 from all published GWAS which has PubMed ID and
SNPs/genes list were updated every six months. We can easily incorporate the information
from GWAS catalog database to validate our finding in GWAS or use it as external reference
to support our finding.
Pathway analysis (also known as gene set analysis) is a useful statistical tool to test DE
gene sets under certain biological function from established pathway databases. A collection
of annotated gene sets for pathway analysis such as molecular signatures database (MSigDB:
http://www.broadinstitute.org/gsea/msigdb/index.jsp), this database contains pre-defined
biological categories such as Gene Ontology (GO); the Kyoto Encyclopedia of Genes and
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Genomes (KEGG); Biocarta gene sets; Reactome gene sets which can be used to perform
the enrichment analysis to understand the underlying biological mechanism. The integrative
analysis incorporated by external databases mentioned above (GWAS and biological pathway
databases) were implemented in Chapter 3.
1.2.3 Integration of family-based data
Next generation sequencing (NGS) is the advanced technology for rare variants detection,
which strongly rely on accurate genotype calls. We can incorporate the family information
from family-based sequencing data because modeling inheritance of alleles can help achieve
more accurate variants and reduce sequencing error in NGS platforms. Chen et al. [2013]
proposed a genotype calling method by considering family structure in trios that can achieve
more accurate genotype calls as compared with one without considering the family structure
(reduce genotype calling error rate by 50%). In chapter 4, we proposed an algorithm to
integrated family information for genotype calling method of complex families.
1.3 MICROARRAY META-ANALYSIS
In this section, I will introduce the microarray meta-analysis for detecting candidate marker
and co-expression module, which motivate me to perform the comparative study of microar-
ray meta-analysis in chapter 2 and developed a co-expression meta-clustering method chapter
3.
1.3.1 Meta-analysis for candidate marker detection
The general steps and key issues for meta-analysis are (1) collect relevant microarray studies
for targeted disease hypothesis; (2) extract useful data sets (for example, raw data, p-values
or effect sizes); (3) the inclusion/exclusion criteria for microarray studies; (4) use appropriate
meta-analysis method to combine multiple studies and (5) analyze data sets and interpret the
results. In steps (1)-(3), our first concern to collect the studies is the heterogeneity between
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studies, which may be caused by different experimental settings, study design, chip platforms,
or statistical method for each individual analysis. For the issue of inclusion/exclusion criteria,
it can be arbitrary chosen by ad-hoc expert opinion, na¨ıve sample size threshold or chip
platforms without an objective quality control procedure. Step (4) and (5) include the
selection of meta-analysis method under certain hypothesis and the result interpretation.
Many microarray meta-analysis methods have been developed and applied in the litera-
ture. First, the most common way to combine multiple studies is to combine p-values from
each single study. The traditional meta-analysis method can be traced back to 1930s, Fisher
[1925] and the minimum p-value method [Tippett et al., 1931], and later new methods were
implemented by Stouffer [Stouffer, 1949] and maximum p-value method [Wilkinson, 1951].
It is well-known that the Fisher statistic follows the chi-square distribution, which can be
dominated by single extremely significant p-value (maybe just simply due to the large sam-
ple sizes). A recent published meta-analysis called adaptive weighted (AW) Fisher’s method
proposed by Li and Tseng [2011] can avoid the potential bias from Fisher’s method. In brief,
the AW Fisher’s method searches through all possible weights to find the best adaptive
weight with the smallest derived p-value from multiple studies and the heterogeneity can be
elucidated. Song and Tseng [2012] developed r-th ordered p-value (rOP) method to consider
a robust form of maximum p-value method to identify markers differentially expressed in
“majority” of studies. Second, another typical meta-analysis method is to combine effect
sizes, either using fixed effect model (FEM) or random effect model (REM). The FEM as-
sumes there is no heterogeneity between studies and the overall effect size was estimated
by weighted effect size from each single study. Misuse of the FEM method to heterogeneity
case will under-estimate the overall effect size (when the underlying assumption of FEM
method was violated). REM method is the one takes heterogeneity between studies into
consideration, which gives different effect size to each single study. The most common vi-
sualization tool for FEM and REM methods is the forest plot, which shows the mean effect
size of single study and its confidence interval (usually 95%) and as well as combined effect.
Third, combining statistical ranks provides another meta-analysis method. The advantage
of the rank-based methods do not require normality assumption and will not be dominated
by extremely small p-value because of the large sample sizes.
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Many meta-analysis methods have been developed and successfully applied to multi-
ple microarray studies, however, there is currently no clear guideline for people to choose
the meta-analysis method properly. In the literature, there were two comparative studies
have systematically compared multiple meta-analysis methods [Hong and Breitling, 2008;
Campain and Yang, 2010], but the conclusion from these two comparative papers were
suggestive with limited insights to guide practitioners. The selection of appropriate meta-
analysis method depends both statistical and biological considerations, and this motivates
the comparative study in chapter 2
1.3.2 Meta-analysis for detecting co-expression module
Gene co-expression study is an alternative way to look at gene changes of transcriptome
studies. Genes are co-expressed if the patterns of expression are highly correlated across
samples in a data set, and may reflect possible shared function by similar expression pattern
between genes. It has been shown co-expressed genes may arise through multiple biological
pathways including cellular co-expression and common regulatory pathways [Lee et al., 2004;
Gaiteri et al., 2010]. In the literature, co-expression analysis have been used to build gene
networks, and to identify communities, modules, or genes with shared functions [Dobrin
et al., 2009; Elo et al., 2007]. In a gene co-expression network, nodes represent genes and
nodes are connected if two corresponding genes are highly correlated (co-expressed). Zhang
et al. [2005] proposed a general framework for weighted gene co-expression network analysis
(WGCNA). They assigns a connection weight for each gene pair to build co-expression
network instead of using a binary index of 0 (unconnected) or 1 (connected). Due to the
instability of module detection in each single study, this motivates me to develop meta-
clustering method to combine multiple microarray studies to construct co-expressed module
in chapter 3.
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1.4 OVERVIEW OF THE THESIS
1.4.1 Comprehensive study of microarray meta-analysis methods
More and more transcriptomic microarray studies have been generated and deposited in the
public domain, such as ArrayExpress from EBI (http://www.ebi.ac.uk/arrayexpress/), Stan-
ford Microarray Database (SMD, http://genome-www5.stanford.edu/), and Gene Expression
Omnibus (GEO) from NCBI (http://www.ncbi.nlm.nih.gov/geo/). In genomic research, mi-
croarray meta-analysis has become popular, which is a set of statistical tools for combining
results (can be p-values, effect sizes or ranks) from multiple studies target on same disease
with similar hypothesis setting. In chapter 2, we proposed a comprehensive comparative
analysis to evaluated 12 meta-analysis methods. First, we categorized the 12 meta-analysis
methods (6 methods combine p values; 2 methods combine effect sizes and 4 methods com-
bine rank statistics were briefly reviewed in the section 2.2.3) according to the three type of
hypothesis the best tested in the simulation study (see more detail section 2.3). Second, four
quantitative evaluation criteria (detection capability, biological association, stability and ro-
bustness) were used in six large-scale microarray applications (each data set contains 4 to
8 studies) to evaluate 12 meta-analysis methods were summarized in section 2.3.3. Third,
we also proposed an entropy measure in section 2.3.5 to understand the data structure of p
values of “homogeneity” or “heterogeneity” between studies if no priori information can be
obtained. Finally in the section 2.4 we will give a guideline to help practitioners select the
proper meta-analysis method in their applications.
1.4.2 Co-expression meta-clustering method and DNA variant Genome Wide
Association Studies
In addition to DE gene analysis, co-expression analysis can be used to investigate the tran-
scriptional co-regulation and gene correlations, and such results can help people build gene
networks, or investigate the modules of genes set with shared biological functions by incorpo-
rating pathway database. In chapter 3, we integrated expression (mRNA level) and GWAS
(SNPs in DNA level) studies of the molecular bases of major depressive disorder (MDD). Our
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central hypothesis is that stable brain co-regulation modules identified by meta-analysis of
multiple transcriptome studies may overlap with sets of genes and associated SNPs related to
MDD. In section 3.2.2, we developed meta-clustering method of gene co-expression analysis
by combining 11 transcriptome studies from postmortem brain of human subjects with major
depressive disorder (MDD) and non-psychiatric controls subjects. Fifty co-expression mod-
ules were identified by clustering using penalized k-medoids [Tseng, 2007], then we performed
enrichment analysis by comparing gene sets identified by GWAS (genes were identified by
significant SNPs within pre-defined nucleotide distance from the coding region of each gene)
for various sets of disorders. In the result and discussion sections, we also compared the
meta-clustering approach by combining co-expression structures from multiple studies with
the clustering result of single study and the performance was evaluated by considering vari-
ous gene sets collected from GWAS. The purpose of this study is to provide insight into the
biology of complex disease such as MDD. First, using robust clustering method to identify
modules from large-scale disease related data sets. Second, incorporating the external re-
sources (for example, GWAS results, pathway database, etc) to identify key network nodes
(genes) from robust module may potentially target to modulate the biological function.
1.4.3 Genotype calling and haplotyping in families
Next generation sequencing (NGS) is the advanced technology which not only looks beyond
the common variants (minor allele frequency > 5%) detected by GWAS, but also systemati-
cally detect the rare variants, which may help us discover the underlying disease mechanisms
more completely. However, next generation sequencing data strongly rely on advanced sta-
tistical and computational methods to generate accurate genotypes and haplotypes. Recent
studies indicated LD-aware approach and using trio-based NGS data set can obtain more
accurate genotype calls and phased haplotypes (Chen et al., 2013; Li et al., 2012). In chap-
ter 4, we extended the current method from analyzing trios to nuclear family or family with
multi-generations with affordable computational complexity. Since many sequencing projects
contain limited sample sizes, we also developed a method to analyze family-based structure
with small sample sizes by incorporating external references as high throughput sequencing
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data sets become available in 1,000 Genomes Project [Abecasis et al., 2010]. In section 4.2.2,
we focused on developing the procedure by looping over all possible parent-offspring trios to
update the probability of observed genotype given the true genotype simultaneously, which
is a pivotal step in the hidden Markov model (HMM). Through simulation studies (see sec-
tion 4.4), we evaluate the performance by using the genotype error calling rate and phasing
error (as haplotypes are provided), and we show that incorporating more offspring within
family (or complex family with multiple generations) can achieve more accurate genotype
calls than trios only, especially in low to modest depth in sequencing data. Specifically, our
new method can help obtain more accurate genotypes by incorporating external references
when analyzing sequencing data with small sample sizes.
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Figure 1: Types of information integration of genomic studies.
(A) Horizontal genomic meta-analysis that combines different sample cohorts for the same
molecular event. (B) Vertical genomic integrative analysis that combines different molecular
events usually in the same sample cohort [Tseng et al., 2012]. “This Figure is used with
permission”
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2.0 META-ANALYSIS METHODS FOR COMBINING MULTIPLE
EXPRESSION PROFILES: COMPARISONS, STATISTICAL
CHARACTERIZATION AND AN APPLICATION GUIDELINE
This paper has been published in BMC bioinformatics Chang et al. [2013].
2.1 INTRODUCTION
Microarray technology has been widely used to identify differential expressed (DE) genes
in biomedical research in the past decade. Many transcriptomic microarray studies have
been generated and made available in public domains such as the Gene Expression Om-
nibus (GEO) from NCBI (http://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress from EBI
(http://www.ebi.ac.uk/arrayexpress/). From the databases, one can easily obtain multiple
studies of a relevant biological or disease hypothesis. Since a single study often has small
sample size and limited statistical power, combining information across multiple studies is
an intuitive way to increase sensitivity. Ramasamy et al. [2008] proposed a seven-step prac-
tical guidelines for conducting microarray meta-analysis: “(i) identify suitable microarray
studies; (ii) extract the data from studies; (iii) prepare the individual datasets; (iv) an-
notate the individual datasets; (v) resolve the many-to-many relationship between probes
and genes; (vi) combine the study-specific estimates; (vii) analyze, present, and interpret
results”. In the first step although theoretically meta-analysis increases the statistical power
to detect DE genes, the performance can deteriorate if problematic or heterogeneous stud-
ies are combined. In many applications, the data inclusion/exclusion criteria are based on
ad-hoc expert opinions, a na¨ıve sample size threshold or selection of platforms without an
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objective quality control procedure. Kang et al. [2012] proposed six quantitative quality
control measures (MetaQC) for decision of study inclusion. Steps (ii)-(v) are related to data
preprocessing. Finally, Steps (vi) and (vii) involve the selection of the meta-analysis method
and interpretation of the result and are the foci of this paper.
Many microarray meta-analysis methods have been developed and applied in the liter-
ature. According to a recent review paper by Tseng et al. [2012], popular methods mainly
combine three different types of statistics: p values, effect sizes and ranks. In this chapter,
we include 12 popular as well as state-of-the-art methods in the evaluation and comparison.
Six methods (Fisher, Stouffer, adaptively weighted Fisher, minimum p value, maximum p
value and r-th ordered p value) belonged to the p value combination category, two methods
(fixed effects model and random effects model) belonged to the effect size combination cate-
gory and four methods (RankProd, RankSum, product of ranks and sum of ranks) belonged
to the rank combination category. Details of these methods and citations will be provided
in the method section. Despite the availability of many methods, pros and cons of these
methods and a comprehensive evaluation remain largely missing in the literature. To our
knowledge, Hong and Breitling [2008] and Campain and Yang [2010] are the only two com-
parative studies that have systematically compared multiple meta-analysis methods. The
number of methods compared (three and five methods, respectively) and the number of real
examples examined (two and three examples respectively with each example covering 2-5 mi-
croarray studies) were, however, limited. The conclusions of the two papers were suggestive
with limited insights to guide practitioners. In addition, as we will discuss in the Method
section, different meta-analysis methods have different underlying hypothesis setting targets.
As a result, the selection of an adequate (or optimal) meta-analysis method depends heavily
on the data structure and the hypothesis setting to achieve the underlying biological goal.
In this chapter, we compare 12 popular microarray meta-analysis methods using simu-
lation and six real applications to benchmark their performance by four statistical criteria
(detection capability, biological association, stability and robustness). Using simulation, we
will characterize the strength of each method under three different hypothesis settings (i.e.
detect DE genes in “all studies”, “majority of studies” or “one or more studies”; see Method
section for more details). We will compare the similarity and grouping of the meta-analysis
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methods based on their DE gene detection results (by using a similarity measure and multi-
dimension scaling plot) and use an entropy measure to characterize the data structure to
determine which hypothesis setting may be more adequate in a given application. Finally,
we give a guideline to help practitioners select the best meta-analysis method under the
choice of hypothesis setting in their applications.
2.2 METHODS
2.2.1 Real data sets
Six example data sets for microarray meta-analysis were collected for evaluation in this
paper. Each example contained 4-8 microarray studies. Five of the six examples were of the
commonly seen two-group comparison and the sixth example contained relapse-free survival
outcome for breast cancer. We applied the MetaQC package to assess quality of the studies
for meta-analysis and determined the final inclusion/exclusion criteria [Kang et al., 2012].
The principal component analysis (PCA) bi-plots and the six QC measures are summarized
in Figure S1 and Table S2 and S3. Details of the data sets are available in Table S1.
2.2.2 Underlying hypothesis settings
Following the classical convention of Birnbaum [1954] and Li and Tseng [2011] (see also Tseng
et al. 2012), meta-analysis methods can be classified into two complementary hypothesis
settings. In the first hypothesis setting (denoted as HSA), the goal is to detect DE genes
that have non-zero effect sizes in all studies:
HSA : H0 :
K⋂
i=1
{θk = 0}versus Ha :
K⋂
k=1
{θk 6= 0} (2.1)
where θk is the effect size if study k. The second hypothesis setting (denoted as HSB),
however, aims to detect a DE gene if it has non-zero effect size in “one or more” studies:
HSB : H0 :
K⋂
i=1
{θk = 0}versus Ha :
K⋃
k=1
{θk 6= 0} (2.2)
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In most applications, HSA is more appropriate to detect conserved and consistent candidate
markers across all studies. However, different degrees of heterogeneity can exist in the studies
and HSB can be useful to detect study-specific markers (e.g. studies from different tissues
are combined and tissue-specific markers are expected and of interest). Since HSA is often
too conservative when many studies are combined, Song and Tseng [2012] proposed a more
practical and robust hypothesis setting (namely HSr) that targets on DE genes with non-zero
effect sizes in “majority” of studies, where majority of studies is defined as, for example, more
than 50% of combined studies (i.e. r ≥ 0.5 ·K). The robust hypothesis setting considered
was:
HS r : H0 :
K⋂
i=1
{θk = 0} versus Ha :
K∑
k=1
I{θk 6= 0} ≥ r (2.3)
A major contribution of this chapter is to characterize meta-analysis methods suitable for
different hypothesis settings (HSA, HSB and HSr) using simulation and real applications and
to compare their performance with four benchmarks to provide a practical guideline.
2.2.3 Implementation and methods
Microarray meta-analysis implementation Assume that we have K microarray studies to
combine. For study k (1 ≤ k ≤ K), denote by xgsk the gene expression intensity of gene
g (1 ≤ g ≤ G) in sample s (1 ≤ s ≤ Sk; Sk the number of samples in study k), and
ysk the disease/outcome variable of sample s. The disease/outcome variable can be binary,
multi-class, continuous or censored, representing the disease state, severity or prognosis
outcome (e.g. tumor versus normal or recurrence survival time). The goal of microarray
meta-analysis is to combine information of K studies to detect differentially expressed (DE)
genes associated with the disease/outcome variable. Such DE genes serve as candidate
markers for disease classification, diagnosis or prognosis prediction and help understand the
genetic mechanisms underlying a disease. In this chapter, before meta-analysis we first
applied penalized t statistics to each individual study to generate p values or DE ranks for
a binary outcome [Tusher et al., 2001]. In contrast to traditional t-statistics, the penalized
t-statistic adds a fudge parameter s0 to stabilize the denominator (T = (X¯ − Y¯ )/(sˆ + s0);
X¯ and Y¯ are means of case and control groups) and to avoid a large t-statistic due to
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small estimated variance sˆ. The p values were calculated using the null distributions derived
from conventional non-parametric permutation analysis by randomly permuting the case and
control labels for 10,000 times [Pesarin and Salmaso, 2010]. For censored outcome variables,
Cox proportion hazard models and log-rank tests were used [Cox, 1972]. Meta-analysis
methods were then used to combine information across studies and generate meta-analyzed
p values. To account for multiple comparisons, the Benjamini and Hochberg procedure was
used to control false discovery rate (FDR) [Benjamini and Hochberg, 1995]. All methods
were implemented using the ”MetaDE” package in R [Wang et al., 2012a]. Data sets and all
programming codes are available at http://www.biostat.pitt.edu/bioinfo/publication.htm.
Microarray meta-analysis methods According to a recent review paper [Tseng et al., 2012],
microarray meta-analysis methods can be categorized into three types: combine p values,
combine effect sizes and combine ranks. Below, we briefly describe 12 methods that were
selected for comparison.
I. Combined p values
Fisher The Fisher’s method sums up the log-transformed p values obtained from individ-
ual studies [Fisher, 1925]. The combined Fisher’s statistic χ2Fisher = −2
∑k
i=1 log(pi) follows a
χ2 distribution with 2k degrees of freedom under the null hypothesis (assuming null p value
are uniformly distributed). Note that we perform permutation analysis instead of such para-
metric evaluation for Fisher and other methods in this paper. Smaller p values contribute
larger scores to the Fisher’s statistic.
Stouffer Stouffer’s method sums the inverse normal transformed p values. Stouffer’s
statistics TStouffer =
∑k
i=1 zi√
k
(zi = Φ
−1(pi), where Φ is standard normal c.d.f) follows a stan-
dard normal distribution under the null hypothesis [Stouffer, 1949]. Similar to Fisher’s
method, smaller p values contribute more to the Stouffer’s score, but in a smaller magni-
tude.
Adaptively weighted (AW) Fisher The AW Fisher’s method assigns different weights to
each individual study (χ2AW = −ΣKk=1wk · log(Pk), wk = 0 or 1) and it searches through
all possible weights to find the best adaptive weight with the smallest derived p value [Li
and Tseng, 2011]. One big advantage of this method is its ability to indicate which studies
contribute to the evidence aggregation and elucidates heterogeneity in the meta-analysis.
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For Fisher, Stouffer and minP methods targeted on HSB, candidate markers differentially
expressed in one or more studies are detected with no indication of which studies are involved
in differential expression. For example, Fisher’s method gives the same statistical significance
for gene A with p values= (0.1, 0.1, 0.1, 0.1) and gene B with p values= (0.0001, 1, 1, 1); the
two genes, however, have very different biological interpretations. The adaptively weighted
Fisher’s method (AW) was developed to improve biological interpretation and statistical
power. AW considered a weighted Fisher score U(w1, ..., wk) = −2
∑
k wk · log pk (where
weight wk equals 0 or 1) and the test statistic was defined as the smallest p value of all
2k − 1 possible weighted Fisher score (i.e. TAW = minw1,...,wK p(U(w1, ..., wK))), where
p(U(w1, ..., wK)) is the p value of U(w1, ..., wk). The resulting best adaptive weight (i.e.
W ∗ = arg minw1,...,wK p(U(w1, ..., wK))) provides indication of which studies contribute to
the statistical significance of meta-analysis. For example, w∗ = (1, 1, 1, 1) for gene A shows
statistical significance in all four studies and w∗ = (1, 0, 0, 0) for gene B shows statistical
significance in only the first study. AW method is admissible under classical two-sample
Gaussian scenario and it generally has better statistical power than traditional Fisher and
minP methods in various kinds of alternative hypothesis in HSB. For more details, refer to
Li and Tseng [2011].
Minimum p value (minP) The minP method takes the minimum p value among the K
studies as the test statistic [Tippett et al., 1931]. It follows a beta distribution with degrees
of freedom α = 1 and β = K under the null hypothesis. This method detects a DE gene
whenever a small p value exists in any one of the K studies.
Maximum p value (maxP) The maxP method takes the maximum p value as the test
statistic [Wilkinson, 1951]. It follows a beta distribution with degrees of freedom α = K and
β = 1 under the null hypothesis. This method targets on DE genes that have small p values
in “all” studies.
r-th ordered p value (rOP) The rOP method takes the r-th order statistic among sorted 
p values of K combined studies. Under the null hypothesis, the statistic follows a beta 
distribution with degrees of freedom α = r and β = K − r + 1. The minP and maxP 
methods are special cases of rOP. In Song and Tseng [2012], rOP is considered a robust form of 
maxP (where r is set as greater than 0.5 · K) to identify candidate markers differentially 
expressed in "majority" of studies.
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II. Combined effect size
Fixed effects model (FEM) FEM combines the effect sizes across K studies by assuming
a simple linear model with an underlying true effect size plus a random error in each study.
Random effects model (REM) REM extends FEM by allowing random effects for the
inter-study heterogeneity in the model [Choi et al., 2003]. The meta-analysis method by
combining effect sizes from several studies is a t-test based modeling approach. The effect size
for a certain gene in the ith study, and i = 1, 2, ..., K is defined as di =
T¯i−C¯i
Si
, where T¯i, C¯i and
Si denote the means of treatment and control group and the estimate of the pooled standard
deviation, respectively. An unbiased estimate for di is obtained as d
′
i = di−3di/(4(ni−2−1))
and the estimated variance of the unbiased effect size is σˆ2di = (n
−1
it +n
−1
ic )+d
2
i ((nit+nic))
−1,
where ni = nit + nic is the sample size in the i
th study; nit and nic are the sample sizes of
treatment and control group in the ith study respectively. From the number of studies k, a
hierarchical model is given as
di = θi + εi, εi ∼ N(0, s2i )
θi = µ+ δi, δi ∼ N(0, τ 2)
where s2i is the variance within certain study k; τ
2 is the variance (random effect) between
studies and µ is the overall mean, which is the parameter of interest. di and s
2
i given by d
′
i
and σˆ2di are described above. τ
2 = 0 means that there is no variance between studies, hence
the hierarchical model reduces to a fixed effects model (FEM), di = µ + εi, εi ∼ N(0, s2i ).
Otherwise, the hierarchical model is a random effects model (REM), di = µ + δi + εi,
εi ∼ N(0, s2i ) and δi ∼ N(0, τ 2). The τˆ 2 can be estimated by a method proposed by
DerSimonian and Laird [1986].
III. Combined rank statistics
RankProd (RP) and RankSum (RS) RankProd and RankSum are based on the common
biological belief that if a gene is repeatedly at the top of the lists ordered by up- or down-
regulation fold change in replicate experiments, the gene is more likely a DE gene [Hong
et al., 2006]. In detail, suppose there are n studies with (niT , niC) replicates, i = 1, 2, ..., k.
Below is the algorithm of finding up-regulated differential genes from Rank Product method
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proposed by Hong et al. [2006]. In the beginning, the pair-wise ratios within each study of
their fold-changes were calculated (i.e., for study i, Tij/Cil, j = 1, 2, ..., niT , l = 1, 2, ..., niC ,
and form ki = niT × niC comparisons:
(1) Define the statistic of rank product RP upg = (ΠiΠkr
up
g,i,k)
1/k, where k = k1 + k2 + · · ·+ kn,
and rupg,i,k is the position of gene g in the list of genes in the i
th study under kth comparison
sorted by decreasing pair-wise ratios calculated before.
(2) Do permutations in each array independently for B times and calculate the statistics
RP
up(1)
g , RP
up(2)
g , ..., RP
up(B)
g , the same in step (1).
(3) The permutation p-value and FDR assessed by permutation within each gene can be
obtained by
pg = (1/GB)ΣbΣgI(|RP up(b)g | ≤ RP upg )
FDRg =
(1/B)
∑
b
∑
g I(|RP up(b)g | ≤ RP upg )∑
g I(|RP up(b)g | ≤ RP upg )
In rank sum (RankSum) method, the statistic RSupg = (
∑
i
∑
k r
up
g,i,k)
1/k was used to
replace the statistic RP upg from the algorithm of rank product (RankProd) mentioned above.
This method only considers gene ranks rather than absolute expression values, which leads
to its robustness against heterogeneity across different studies.
Product of ranks (PR) and Sum of ranks (SR) These two methods apply a na¨ıve product
or sum of the DE evidence ranks across studies Dreyfuss et al. [2009]. Suppose Rgk represents
the rank of p value of gene g among all genes in study k. The test statistics of PR and SR
are calculated as PRg =
∏K
k=1Rgk and SRg =
∑K
k=1Rgk, respectively. P values of the test
statistics can be calculated analytically or obtained from a permutation analysis. Note that
the ranks taken from the smallest to largest (the choice in the method) are more sensitive
than ranking from largest to smallest in the PR method, while it makes no difference to SR.
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2.2.4 Characterization of meta-analysis methods
MDS plots to characterize the methods The multi-dimensional scaling (MDS) plot is a use-
ful visualization tool for exploring high-dimensional data in a low-dimensional space [Borg,
2005]. In the evaluation of 12 meta-analysis methods, we proposed a similarity measure
between two ordered DE gene list (more detail in the section 2.2.6) for every pair of methods
to quantify the similarity of their DE analysis results in a given example. A dissimilarity
measure is then defined as one minus the adjusted DE similarity measure and the dissimilar-
ity measure is used to generate an MDS plot of the 12 methods. In the MDS plot, methods
that are clustered in a neighbourhood indicate that they produce similar DE analysis results.
Entropy measure to characterize data sets As indicated in the Section of underlying hypoth-
esis settings, selection of the most suitable meta-analysis method(s) largely depends on their
underlying hypothesis setting (HSA, HSB and HSr). The selection of a hypothesis setting for
a given application should be based on the experimental design, biological knowledge and the
associated analytical objectives. There are, however, occasions that little prior knowledge or
preference is available and an objective characterization of the data structure is desired in a
given application. For this purpose, we developed a data-driven entropy measure to charac-
terize whether a given meta-analysis data set contains more HSA-type markers or HSB-type
markers [Martin and England, 2011]. The algorithm is described below:
1. Apply Fisher’s meta-analysis method to combine p values across studies to identify the
top H candidate markers. Here we use H = 1, 000. H represents the rough number of
DE genes (in our belief) that are contained in the data.
2. For each selected marker, we defined the standardized minus p value score for gene g
in the kth study as lgk = − log(pgk)/ −
∑K
k=1 log(pgk). Note that 0 ≤ lgk ≤ 1, large lgk
corresponds to more significant p value pgk, and
∑K
k=1 lgk = 1.
3. The entropy of gene g is defined as eg = −
∑K
k=1 lgk log(lgk). A box-plots of entropies of
the top H genes is generated for each meta-analysis application.
Intuitively, a high entropy value indicates that the gene has small p values in all or most
studies and is of HSA or HSr-type. Conversely, genes with small entropy have small p values
in one or only few studies where HSB-type methods are more adequate. When calculating
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lgk in step 2, we capped − log(pgk) at 10 to avoid contributions of close-to-zero p values that
can generate near-infinite scores. The entropy box-plots helps determine an appropriate
meta-analysis hypothesis setting if no pre-set biological objective exists.
2.2.5 Evaluation criteria
For objective quantitative evaluation, we developed the following four statistical criteria to
benchmark performance of the methods.
Detection capability The first criterion considers the number of DE genes detected by
each meta-analysis method under the same pre-set FDR threshold (e.g. FDR= 1%). Al-
though detecting more DE genes does not guarantee better “statistical power”, this cri-
terion has served as a surrogate of statistical power in previous comparative studies [Wu
et al., 2005]. An implicit assumption underlying this criterion is that the statistical pro-
cedure to detect DE genes in each study and the FDR control in the meta-analysis are
accurate (or roughly accurate). To account for data variability in the evaluation, we boot-
strapped (i.e. sampled with replacement) the samples in each study for B = 50 times and
calculated the number of detected DE genes under the pre-set FDR threshold with 5%. De-
note by rmeb the rank of detection power performance (the smaller the better) of method
m (1 ≤ m ≤ 12) in example e (1 ≤ e ≤ 6) and in the bth 1 ≤ b ≤ 50 bootstrap sim-
ulation. The mean standardized rank (MSR) for method m and example e is calculated
as MSRme =
∑B
b=1(rmeb/#of methods compared)/B and the aggregated standardized rank
(ASR) is calculated as ASRm =
∑6
e=1(MSRme)/6, representing the overall performance of
method m across all six examples. Table S4 shows the MSR and ASR of all 12 methods and
Figure 3 (in the result section) shows plot of mean number of detected DE genes with error
bars of standard errors for each method ordered by ASR. We note that MSR and ASR are
both standardized between 0 and 1. The standardization in MSR is necessary because in
the breast cancer survival example we cannot apply FEM, REM, RankSum and RankProd
as they are developed only for a two-group comparison.
Biological association The second criterion requires that a good meta-analysis method
should detect a DE gene list that has better association with pre-defined “gold standard”
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pathways related to the targeted disease. Such a “gold standard” pathway set should
be obtained from biological knowledge for a given disease or biological mechanism un-
der investigation. However, since it is well-known that pathway collections are always
incomplete and erroneous, such prior knowledge may be missing or arguable by differ-
ent experts. To facilitate this evaluation without bias, we developed a computational
and data-driven approach to determine a set of surrogate disease-related pathways out
of a large collection of pathways by combining pathway enrichment analysis results from
each single study. Specifically, we first collected 2,287 pathways (gene sets) from MSigDB
(http://www.broadinstitute.org/gsea/msigdb/): 1,454 pathways from “GO,” 186 pathways
from “KEGG,” 217 pathways from “BIOCARTA” and 430 pathways from “REACTOME”,
respectively. We filtered out pathways with less than 5 genes or more than 200 genes and
2,113 pathways were left for the analysis. DE analysis was performed in each single study
separately and pathway enrichment analysis was performed for all the 2,113 pathways by the
Kolmogorov-Smirnov (KS) association test. Denote by puk the resulting pathway enrichment
p value for pathway u (1 ≤ u ≤ 2, 113) and study k (1 ≤ k ≤ K). For a given study k,
enrichment ranks over pathways were calculated as ruk = ranku(puk). A rank-sum score for
a given pathway u was then derived as su =
∑K
k=1 ruk. Intuitively, pathways with small
rank-sum scores indicate that they are likely associated with the disease outcome by aggre-
gated evidence of the K individual study analyses. We chose the number of top D pathways
that had the smallest rank-sum scores as the surrogate disease-related pathways and used
these to proceed with the biological association evaluation of meta-analysis methods in the
following.
Given the selected surrogate pathways D, the following procedure was used to evaluate
performance of the 12 meta-analysis methods for a given example e (1 ≤ e ≤ 6). For each
meta-analysis method m (1 ≤ m ≤ M = 12), the DE analysis result was associated with
pathway u and the resulting enrichment p value by KS-test was denoted by P˜med (1 ≤ d ≤ D).
The rank of P˜med for method m among 12 methods was denoted by vmed = rankm(P˜med).
Similar to the detection power evaluation, we calculated the mean standardized rank (MSR)
for method m and example e as MSRme =
∑D
d=1(vmeb/#of methods compared)/D and the
aggregated standardized rank (ASR) as ASRm =
∑6
e=1(MSRme)/6, representing the overall
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performance of method m. To select the parameter D for surrogate disease-related pathways,
Supplement Figure S4 shows the trend of MSRme (on the y-axis) versus D (on the x-axis)
as D increases. The result indicated that the performance evaluation using different D only
minimally impacted the conclusion when D > 30. We choose D = 100 throughout this
paper.
Note that we used the KS test, instead of the popular Fisher’s exact test because each
single study detected variable number of DE genes under a given FDR cutoff and the Fisher’s
exact test is usually not powerful unless a few hundred DE genes are detected. On the other
hand, the KS test does not require an arbitrary p value cutoff to determine the DE gene list
for enrichment analysis.
Stability The third criterion examines whether a meta-analysis method generates stable
DE analysis results. To achieve this goal, we randomly split samples into half in each study
(so that cases and controls are as equally split as possible). The first half of each study
was taken to perform the first meta-analysis and generate a DE analysis result. Similarly,
the second half of each study was taken to perform a second meta-analysis. The generated
DE analysis results from two separate meta-analyses were compared by the adjusted DE
similarity measures (described in the next section). The procedure was repeated for B = 50
times. Denote by Smeb the adjusted DE similarity measure of method m of the b
th simulation
in example e. Similar to the first two criteria, MSR and ASR are calculated based on Smeb
to evaluate the methods.
Robustness The final criterion investigates the robustness of a meta-analysis method
when an outlying study is randomly added to the meta-analysis. For each of the six real
examples, we randomly picked one irrelevant study from the other five examples and added
it to the meta-analysis. The adjusted DE similarity measure was calculated between the
original meta-analysis and the new meta-analysis with an added outlier. A higher adjusted
similarity measure shows better robustness againt inclusion of the outlying study. This
procedure is repeated until all irrelevant studies are used. The MSR and ASR are then
calculated based on the adjusted DE similarity measures to evaluate the methods.
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2.2.6 Similarity measure between two ordered DE gene lists
To compare results of two DE detection methods (from single study analysis or meta-
analysis), a commonly used method in the literature is to take the DE genes under a certain
p value or FDR threshold, plot the Venn diagram and compute the ratio of overlap. This
method, however, greatly depends on the selection of the FDR threshold and is unstable.
Another approach is to take the generated ordered DE gene lists from two methods and com-
pute the non-parametric Spearman rank correlation [Spearman, 1904]. This method avoids
the arbitrary FDR cutoff but gives, say, the top 100 important DE genes and the bottom
100 non-DE genes equal contribution. To circumvent this pitfall, Li et al. [2011] proposed a
parametric reproducibility measure for ChIP-seq data in the ENCODE project. Yang et al.
[2006] introduced an OrderedList measure to quantify similarity of two ordered DE gene
lists. For simplicity, we extended the OrderedList measure into a standardized similarity
score for the evaluation purpose in this paper. Specifically, suppose G1 and G2 are two
ordered DE gene lists (e.g. ordered by p values) and small ranks represent more significant
DE genes. We denote by On(G1, G2) the number of overlapped genes in the top n genes of
G1 and G2. As a result, 0 ≤ On(G1, G2) ≤ n and a large On(G1, G2) value indicates high
similarity of the two ordered lists in the top n genes. A weighted average similarity score is
calculated as S(G1, G2) =
∑G
n=1 e
−αn ·On(G1, G2), where G is the total number of matched
genes and the power α controls the magnitude of weights emphasized on the top ranked
genes. When α is larger top ranked genes are weighted higher in the similarity measure.
The expected value (under the null hypothesis that the two gene rankings are randomly gen-
erated) and maximum value of S can be easily calculated: Enull(S(G1, G2)) =
∑G
n=1 e
−αn · n2G
and max(S(G1, G2)) =
∑G
n=1 e
−αn · n We apply an idea similar to the adjusted Rand index
[Hubert and Arabie, 1985] used to measure similarity of two clustering results and define the
adjusted DE similarity measure as
S∗(G1, G2) =
S(G1, G2)− Enull(S(G1, G2))
max(S(G1, G2))− Enull(S(G1, G2)) (2.4)
This measure ranges between −1 to 1 and gives an expected value of 0 if two ordered gene
lists are obtained by random chance. Yang et al. [2006] proposed a resampling-based ROC
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method to estimate the best selection of α. Since the number of DE genes in our examples
is generally high, we choose a relatively small α = 0.001 throughout this paper. We have
tested different α and found that the results were similar (Figure S7).
2.3 RESULTS
2.3.1 Simulation setting
We conducted simulation studies to evaluate and characterize the 12 meta-analysis methods
for detecting biomarkers in the underlying hypothesis settings of HSA, HSB or HSr. The
simulation algorithm is described below:
1. We simulated 800 genes with 40 gene clusters (20 genes in each cluster) and other 1,200
genes do not belong to any cluster. The cluster indexes Cg for gene g(1 ≤ g ≤ 2, 000)
were randomly sampled, such that
∑
I{Cg = 0} = 1, 200 and
∑
I{Cg = c} = 20, (1 ≤
c ≤ 40).
2. For genes in cluster c(1 ≤ c ≤ 40) and in study k(1 ≤ k ≤ 5), we sampled ∑′ck ∼
W−1(Ψ, 60), where Ψ = 0.5I20×20 + 0.5J20×20, W−1 denotes the inverse Wishart distri-
bution, I is the identity matrix and J is the matrix with all elements equal 1. We then
standardized
∑′
ck into
∑
ck, where the diagonal elements are all 1’s.
3. 20 genes in cluster c was denoted by the index of gc1,...,gc20 , i.e. Cgcj = c, where 1 ≤ c ≤ 40
and 1 ≤ j ≤ 20. We sampled gene expression levels of genes in cluster c for sample n as
(X
′
gc1nk
, . . . , X
′
gc20nk
)
T ∼ MVN(0,∑ck) where 1 ≤ n ≤ 100 and 1 ≤ k ≤ 5, and sample
expression level for the gene g ∼ N(0, σ2k) which is not in any cluster for sample n, where
1 ≤ n ≤ 100, 1 ≤ k ≤ 5 and σ2k was uniformly distributed from [0.8, 1.2], which indicates
different variance for study k.
4. For the first 1,000 genes (1 ≤ g ≤ 1, 000), kg (the number of studies that are differentially
expressed for gene g) was generated by sampling kg = 1, 2, 3, 4, 5, respectively. For the
next 1,000 genes (1, 001 ≤ g ≤ 2, 000), kg = 0 represents non-DE genes in all five studies.
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5. To simulate expression intensities for cases, we randomly sampled δgk ∈ {0, 1}, such that∑
k δgk = kg. If δgk = 1, gene g in study k was a DE gene, otherwise it was a non-DE
gene. When δgk = 1, we sampled expression intensities µgk from a uniform distribution
in the range of [0.5, 3], which means we considered the concordance effect (up-regulated)
among all simulated studies. Hence, the expression for control samples are Xgnk = X
′
gnk,
and case samples are Ygnk = X
′
g(n+50)k + µgk · δgk, for 1 ≤ g ≤ 2, 000, 1 ≤ n ≤ 50 and
1 ≤ k ≤ 5
In the simulation study, we had 1,000 non-DE genes in all five studies (kg = 0), and 1,000
genes were differentially expressed in 1 − 5 studies (kg = 1, 2, 3, 4, 5). On average, we had
roughly the same number (∼ 200) of genes in each group of kg = 1, 2, 3, 4, 5. See Figure S2
for the heatmap of a simulated example (red represents up-regulated genes). We applied the
12 meta-analysis methods under FDR control at 5%. With the knowledge of true kg, we were
able to derive the sensitivity and specificity for HSA and HSB, respectively. In HSA, genes
with kg = 5 were the underlying true positives and genes with kg = 0−4 were the underlying
true negatives; in HSB, genes with kg = 1− 5 were the underlying true positives and genes
with kg = 0 were the true negatives. By adjusting the decision cutoff, the receiver operating
characteristic (ROC) curves and the resulting area under the curve (AUC) were used to
evaluate the performance. We simulated 50 data sets and reported the means and standard
errors of the AUC values. AUC values range between 0 and 1. AUC= 50% represents a
random guess and AUC= 1 reaches the perfect prediction. The above simulation scheme
only considered the concordance effect sizes (i.e. all with up-regulation when a gene is DE in
a study) among five simulated studies. In many applications, some genes may have p-value
statistical significance in the meta-analysis but the effect sizes are discordant (i.e. a gene is
up-regulation in one study but down-regulation in another study). To investigate that effect,
we performed a second simulation that consider random discordant cases. In step 5, the µgk
became a mixture of two uniform distributions: pigk ·Unif [−3,−0.5]+(1−pigk) ·Unif [0.5, 3],
where pigk is the probability of gene g(1 ≤ g ≤ 2, 000) in study k(1 ≤ k ≤ 5) to have
a discordant effect size (down-regulated). We set pigk = 0.2 for the discordant simulation
setting.
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2.3.2 Simulation results to characterize the methods
The simulation study provided the underlying truth to characterize the meta-analysis meth-
ods according to their strengths and weaknesses for detecting DE genes of different hypothesis
settings. The performances of 12 methods were evaluated by receiver operating characteris-
tic (ROC) curves, which is a visualization tool that illustrates the sensitivity and specificity
trade-off, and the resulting area under the ROC curve (AUC) under two different hypothesis
settings of HSA and HSB. Table 1 shows the detected number of DE genes under nomi-
nal FDR at 5%, the true FDR and AUC values under HSA and HSB for all 12 methods.
The values were averaged over 50 simulations and the standard errors are shown in the
parentheses.
Figure 2 shows the histograms of the true number of DE studies (i.e. kg) among the
detected DE genes under FDR= 5% for each method. It is clearly seen that minP, Fisher,
AW, Stouffer and FEM detected HSB-type DE genes and had high AUC values under HSB
criterion (0.98-0.99), compared to lower AUC values under HSA criterion (0.79-0.9). For
these methods, the true FDR for HSA generally lost control (0.41-0.44). On the other hand,
maxP, rOP and REM had high AUC under HSA criterion (0.96-0.99) (true FDR = 0.068-
0.117) compared to HSB (0.75-0.92). maxP detected mostly HSA-type of markers and rOP
and REM detected mostly HSr-type DE genes. PR and SR detected mostly HSA-type DE
genes but they surprisingly had very high AUC under both HSA and HSB criteria. The
RankProd method detected DE genes between HSr and HSB types and had a good AUC
value under HSB. The RankSum detected HSB-type DE genes but had poor AUC values
(0.5) for both HSA and HSB. Table 1 includes our concluding characterization of the targeted
hypothesis settings for each meta-analysis method (see also Figure S5 of the ROC curve and
AUC of HSA-type and HSB-type in 12 meta-analysis methods). Figure S3 shows the result
for the second discordant simulation setting. The numbers of studies with opposite effect size
are represented by different colours in histogram plot (green: all studies with concordance
effect size; blue: one study has opposite effect size with the remaining; red: two studies have
opposite effect size with the remaining). In summary, almost all meta-analysis methods could
not avoid inclusion of genes with opposite effect sizes. Particularly, methods utilizing p-values
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from two-sided tests (e.g. Fisher, AW, minP, maxP and rOP) could not distinguish direction
of effect sizes. Stouffer was the only method that accommodated the effect size direction
in its z-transformation formulation but its ability to avoid DE genes with discordant effect
sizes seemed still limited. Owen [2009] proposed a one-sided correction procedure for Fishers
method to avoid detection of discordant effect sizes in meta-analysis. The null distribution
of the new statistic, however, became difficult to derive. The approach can potentially be
extended to other methods and more future research will be needed for this issue.
2.3.3 Results of the four evaluation criteria
Detection capability Figure 3 shows the number of DE genes identified by each of the 12
meta-analysis methods (FDR= 10% for MDD and breast cancer due to their weak signals
and FDR= 1% for all the others). Each plot shows mean with error bars of standard error
for 50 bootstrapped data sets. Table S4 shows the MSR and ASR for each method in the
six examples. The methods in Figure 3 are ordered according to their ASR values. The
top six methods with the strongest detection power were those that detected HSB-type DE
genes from the conclusion of Table 1: Fisher, AW, Stouffer, minP, FEM and RankSum. The
order of performance of these six methods was pretty consistent across all six examples. The
next four methods were rOP, RankProd, maxP and REM and they targeted on either HSr
or HSA. PR and SR had the weakest detection capability, which was consistent with the
simulation result in Table 1.
Biological association Figure 4 shows plots of mean with error bars of standard error from
the pathway association p values (minus log-transformed) of the top 100 surrogate disease-
related pathways for the 12 methods. Table S5 shows the corresponding MSR and ASR.
We found that Stouffer, Fisher and AW had the best performance among the 12 methods.
Surprisingly we found that although PR and SR had low detection capability in simulation
and real data, they consistently had relatively high biological association results. This may
be due to the better DE gene ordering results these two methods provide, as was also shown
by the high AUC values under both hypothesis settings in the simulation.
Stability Figure 5 shows the plots of mean with error bars of standard error of stability
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calculated by adjusted DE similarity measure. Table S6 contains the corresponding MSR
and ASR. In summary, RankProd and RankSum methods were the most stable meta-analysis
methods probably because these two nonparametric approaches take into account all possible
fold change calculations between cases and controls. They do not need any distributional
assumptions, which provided stability even when sample sizes were small [Breitling and
Herzyk, 2005]. The maximum p value method consistently had the lowest stability in all
data sets, which is somewhat expected. For a given candidate marker with a small maximum
p value, the chance that at least one study has significantly inflated p values is high when
sample size is reduced by half. The stability measures in the breast cancer example were
generally lower than other examples. This is mainly due to the weak signals for survival
outcome association, which might be improved if larger sample size is available.
Robustness Figure 6 shows the plots of mean with error bard of standard error of robustness
calculated by adjusted DE similarity measure between the original meta-analysis and the
new meta-analysis with an added outlier. Table S7 shows the corresponding MSR and ASR
values. In general, methods suitable for HSB (minP, AW, Fisher and Stouffer) have better
robustness than methods for HSA or HSr (e.g. maxP and rOP). The trend is consistent in
the prostate cancer, brain cancer and IPF examples but is more variable in the weak-signal
MDD and breast cancer examples. RankSum was surprisingly the most sensitive method to
outliers, while RankProd performs not bad.
2.3.4 Characterization of methods by MDS plots
We applied the adjusted DE similarity measure to quantify the similarity of the DE gene or-
ders from any two meta-analysis methods. The resulting dissimilarity measure (i.e. one
minus adjusted similarity measure) was used to construct the multidimensional scaling
(MDS) plot, showing the similarity/dissimilarity structure between the 12 methods in a
two-dimensional space. When two methods were close to each other, they generated similar
DE gene ordering. The patterns of MDS plots from six examples generated quite consistent
results (Figure S6). Figure 7(a) shows an aggregated MDS plot where the input dissimilarity
matrix is averaged from the six examples. We clearly observed that Fisher, AW, Stouffer,
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minP, PR and SR were consistently clustered together in all six individual and the aggre-
gated MDS plot (labeled in red). This is not surprising given that these methods all sum
transformed p value evidence across studies (except for minP). Two methods to combine ef-
fect sizes and two methods to combine ranks (FEM, REM, RankProd and RankSum labeled
in blue) are consistently clustered together. Finally, the maxP and rOP methods seem to
form a third loose cluster (labeled in green).
2.3.5 Characterization of data sets by entropy measure
From the simulation study, selection of a most suitable meta-analysis method depends on the
hypothesis setting behind the methods. The choice of a hypothesis setting mostly depends
on the biological purpose of the analysis; that is, whether one aims to detect candidate
markers differentially expressed in “all” (HSA), “most” (HSr) or “one or more” (HSB) studies.
However, when no biological prior information or preference exists, the entropy measure can
be objectively used to determine the choice of hypothesis setting. The analysis identifies
the top 1,000 genes from Fisher’s meta-analysis method and the gene-specific entropy of
each gene is calculated. When the entropy is small, the p values are small in only one or
very few studies. Conversely, when the entropy is large, most or all of the studies have
small p values. Figure 7(b) shows the box-plots of entropy of the top 1,000 candidate genes
identified by Fisher’s method in the six data sets. The result shows that prostate cancer
comparing primary and metastatic tumor samples had the smallest entropy values, which
indicated high heterogeneity across the three studies and that HSB should be considered
in the meta-analysis. On the other hand, MDD had the highest entropy values. Although
the signals of each MDD study were very weak, they were rather consistent across studies
and application of HSA or HSr was adequate. For the other examples, we suggest using the
robust HSr unless other prior biological purpose is indicated.
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2.4 CONCLUSIONS AND DISCUSSIONS
2.4.1 An application guideline for practitioners
From the simulation study, the 12 meta-analysis methods were categorized into three hy-
pothesis settings (HSA, HSB and HSr), showing their strengths for detecting different types
of DE genes in the meta-analysis (Figure 2 and the second column of Table 2). For exam-
ple, maxP is categorized to HSA since it tends to detect only genes that are differentially
expressed in all studies. From the results using four evaluation criteria, we summarized the
rank of ASR values (i.e. the order used in Figure 3- Figure 6) and calculated the rank sum
of each method in Table 2. The methods were then sorted first by the hypothesis setting
categories and then by the rank sum. The clusters of methods from the MDS plot were also
displayed. For methods in the HSA category, we surprisingly see that the maxP method
performed among the worst in all four evaluation criteria and should be avoided. PR was
a better choice in this hypothesis setting although it provides a rather weak detection ca-
pability. For HSB, Fisher, AW and Stouffer performed very well in general. Among these
three methods, we note that AW has an additional advantage to provide an adaptive weight
index that indicates the subset of studies contributing to the meta-analysis and characterizes
the heterogeneity (e.g. adaptive weight (1,0,...) indicates that the marker is DE in study
1 but not in study 2, etc.). As a result, we recommend AW over Fisher and Stouffer in
the HSB category. For HSr, the result was less conclusive. REM provided better stability
and robustness but sacrificed detection capability and biological association. On the other
hand, rOP obtained better detection capability and biological association but was neither
stable nor robust. In general, since detection capability and biological association are of
more importance in the meta-analysis and rOP has the advantage to link the choice of r in
HSr with the rOP method (e.g. when r = 0.7 · K, we identify genes that are DE in more
than 70% of studies), we recommend rOP over REM.
Below, we provide a general guideline for a practitioner when applying microarray meta-
analysis. Data sets of a relevant biological or disease hypothesis are firstly identified, prepro-
cessed and annotated according to Step (i) - (v) in Ramasamy et al. [2008]. Proper quality
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assessment should be performed to exclude studies with problematic quality (e.g. with the
aid of MetaQC as we did in the six examples). Based on the experimental design and bi-
ological objectives of collected data, one should determine whether the meta-analysis aims
to identify biomarkers differentially expressed in all studies (HSA), in one or more studies
(HSB) or in majority of studies (HSr). In general, if higher heterogeneity is expected from,
say, heterogeneous experimental protocol, cohort or tissues, HSB should be considered. For
example, if the combined studies come from different tissues (e.g. the first study uses periph-
eral blood, the second study uses muscle tissue and so on), tissue-specific markers may be
expected and HSB should be applied. On the contrary, if the collected studies are relatively
homogeneous (e.g. use the same array platform or from the same lab), HSr is generally
recommended, as it provides robustness and detects consistent signals across the majority of
studies. In the situation that no prior knowledge is available to choose a desired hypothesis
setting or if the researcher is interested in a data-driven decision, the entropy measure in
Figure 7(b) can be applied and the resulting box-plot can be compared to the six examples
in this paper to guide the decision. Once the hypothesis setting is determined, the choice of
a meta-analysis method can be selected from the discussion above and Table 2.
2.4.2 Conclusion
In this paper, we performed a comprehensive comparative study to evaluate 12 microarray
meta-analysis methods using simulation and six real examples with four evaluation criteria.
We clarified three hypothesis settings that were implicitly assumed behind the methods.
The evaluaion results produced a practical guideline to inform biologists the best choice of
method(s) in real applications.
With the reduced cost of high-throughput experiments, data from microarray, new se-
quencing techniques and mass spectrometry accumulate rapidly in the public domain. In-
tegration of multiple data sets has become a routine approach to increase statistical power,
reduce false positives and provide more robust and validated conclusions. The evaluation
in this paper focuses on microarray meta-analysis but the principles and messages apply
to other types of genomic meta-analysis (e.g. GWAS, methylation, miRNA and eQTL).
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When next-generation sequencing technology becomes more affordable, sequencing data will
become more prevalent as well and similar meta-analysis techniques will apply. For these dif-
ferent types of genomic meta-analysis, similar comprehensive evaluation could be performed
and application guidelines should be established as well.
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Figure 2: The histograms of the true number of DE studies were detected as DE
genes under FDR = 5% in each method.
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Table 1: The detected number of DE genes (at FDR= 5%), the true FDR, AUC values
under HSA and HSB and the concluding characterization of targeted hypothesis setting of
each method.
maxP rOP minP Fisher AW Stouffer
detected # 321 522 1005 1000 1000 974
(se) (2.2) (2.35) (0.85) (1.06) (1.05) (1.5)
True FDR (HSA) 0.068 0.18 0.447 0.444 0.444 0.43
(se) (0.008) (0.012) (0.0006) (0.0007) (0.0008) (0.0009)
True FDR (HSB) 0.007 0.011 0.016 0.017 0.016 0.022
(se) (0.0005) (0.0004) (0.0006) (0.0006) (0.0007) (0.0006)
AUC (HSA) 0.996 0.964 0.8 0.82 0.79 0.89
(se) (0.0003) (0.0014) (0.0005) (0.0005) (0.0005) (0.0006)
AUC (HSB) 0.75 0.833 0.99 0.99 0.99 0.99
(se) (0.0013) (0.01) (0.0001) (0.0001) (0.0001) (0.0005)
Characterization HSA HSr HSB HSB HSB HSB
PR SR FEM REM RankProd RankSum
detected # 136 186 948 411 391 105
(se) (2.51) (2.3) (1.75) (2.86) (3.31) (1.514)
True FDR (HSA) 0.008 0.01 0.415 0.117 0.13 0.389
(se) (0.0003) (0.0004) (0.0009) (0.0015) (0.0014) (0.0008)
True FDR (HSB) 0 0 0.022 0.007 0 0
(se) (0) (0) (0.0007) (0.0004) (0) (0)
AUC (HSA) 0.986 0.99 0.917 0.99 0.916 0.504
(se) (0.0003) (0.0002) (0.0009) (0.0002) (0.0011) (0.0046)
AUC (HSB) 0.981 0.95 0.984 0.92 0.934 0.496
(se) (0.0004) (0.0008) (0.0004) (0.0011) (0.0012) (0.0025)
Characterization HSA HSA HSB HSr HSB HSB
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Figure 3: The plot of mean numbers of detected DE genes with error bars of
standard error from 50 bootstrapped data sets for the 12 meta-analysis methods.
Note that FEM, REM, RankProd and RankSum cannot be applied to survival
examples.
35
l l l
l
l
l
l
l
l
l l
l
Prostate Cancer (Normal v.s Primary)
−
lo
g1
0(P
) 
0
1
2
3
4
5
l l l
l l l
l
l
l l l
l
Prostate Cancer (Primary v.s Metastasis)
0
1
2
3
4
5
l l l
l
l
l
l
l l l l
l
Brain Cancer (AA v.s GBM)
−
lo
g1
0(P
) 
0
1
2
3
4
5
l
l
l
l
l
l
l
l
l
l
l l
MDD
0
1
2
3
4
5
l
l
l
l
l
l
l
l
l
l
l
l
IPF
−
lo
g1
0(P
) 
0
1
2
3
4
5
St
ou
ffe
r
Fi
sh
er
AW P
R
rO
P
SR m
in
P
R
an
kP
ro
d
FE
M
m
ax
P
R
EM
R
an
kS
um
l
l l l
l
l l
l
Breast Cancer
0
1
2
3
4
5
St
ou
ffe
r
Fi
sh
er
AW P
R
rO
P
SR m
in
P
R
an
kP
ro
d
FE
M
m
ax
P
R
EM
R
an
kS
um
Figure 4: Plot of mean values of − log10(p) with error bars of standard error
from KS-test based on the top 100 surrogate pathways. Note that FEM, REM,
RankProd and RankSum cannot be applied to survival examples.
36
l l
l l
l
l
l
l
l
l
l
l
Prostate Cancer (Normal v.s Primary)
Ad
jus
ted
 si
mi
lar
ity
 m
ea
su
re
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
l l
l l l l l l l l
l
l
Prostate Cancer (Primary v.s Metastasis)
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
l l
l l l l
l
l l
l
l
l
Brain Cancer (AA v.s GBM)
Ad
jus
ted
 si
mi
lar
ity
 m
ea
su
re
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
l l
l l
l
l l
l
l
l
l
l
MDD
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
l l
l
l
l l l
l
l
l
l
l
IPF
Ad
jus
ted
 si
mi
lar
ity
 m
ea
su
re
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
R
an
kP
ro
d
R
an
kS
um
Fi
sh
er
PR R
EM AW m
in
P
St
ou
ffe
r
SR rO
P
FE
M
m
ax
P
l l l l l l l l
Breast Cancer
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
R
an
kP
ro
d
R
an
kS
um
Fi
sh
er
PR R
EM AW m
in
P
St
ou
ffe
r
SR rO
P
FE
M
m
ax
P
Figure 5: Plot of mean with error bars of standard error of stability in six
examples based on the adjusted similarity between DE results of two randomly
split data sets. Note that FEM, REM, RankProd and RankSum cannot be
applied to survival examples.
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Figure 6: Plots of mean with error bars of standard error of robustness in six ex-
amples based on the adjusted similarity between DE results with/without adding
one irrelevant noise study. Note that FEM, REM, RankProd and RankSum can-
not be applied to survival examples.
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(a)
(b)
Figure 7: (a) Multi-dimensional scaling (MDS) plot of all 12 methods based on
the average dissimilarity matrix of six examples. Colors (red, green and blue)
indicate clusters of methods with similar DE detection ordering. (b) The box-
plots of entropies in six data sets. High entropies indicate that high consistency
of DE gene detection across studies (e.g. MDD). Low entropies show greater
heterogeneity in DE gene detection (e.g. prostate cancer).
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Table 2: Ranks of method performance in the four evaluation criteria.
Targeted Detection Biological Stability Robustness Rank MDS∗1
HS Capability Association Sum
PR HSA 12 4 4 6 26 1
SR HSA 11 6 9 7 33 1
maxP HSA 9 10 12 11 42 2
rOP HSr 7 5 10 10 32 2
REM HSr 10 11 5 8 34 3
Fisher HSB 1 2 3 3 9 1
AW HSB 2 3 6 2 13 1
Stouffer HSB 3 1 8 4 16 1
minP HSB 4 7 7 1 19 1
RankProd HSB 8 8 1 5 22 3
RankSum HSB 6 12 2 12 32 3
FEM HSB 5 9 11 9 34 3
∗1: same number means the methods are clustered together in MDS plot
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3.0 A CONSERVED BDNF, GLUTAMATE-, GABA-ENRICHED GENE
MODULE RELATED TO HUMAN DEPRESSION IDENTIFIED BY GENE
COEXPRESSION META-ANALYSIS AND DNA VARIANT
GENOME-WIDE ASSOCIATION STUDIES
This paper has been published in BMC bioinformatics Chang et al. [2014].
3.1 INTRODUCTION
Major depressive disorder (MDD) is a common psychiatric disease with an estimated preva-
lence 3% for a current episode and 5.2% for a lifetime disorder [Hasin et al., 2005],a high rate
of recurrence [Mueller et al., 1999], a higher prevalence in women [Weissman et al., 1993], and
a heritability of 37% (95% CI = 31% - 42%) [Sullivan et al., 2000]. Transcriptome (the set
of all expressed genes in a tissue sample) and genome-wide association studies (GWAS) have
separately provided clues to mechanisms of MDD, although not to the anticipated extent.
Transcriptome studies mostly focus on changes in gene expression in disease states (altered
expression), but also provide unique opportunities for assessing the less-investigated changes
in the coordinated function of multiple genes (altered coexpression) [Gaiteri et al., 2013],
2013. GWAS seek to identify genetic markers for diseases, and have generated some findings
in MDD [Rietschel et al., 2010; Shi et al., 2010; Muglia et al., 2008; Lewis et al., 2010;
Shyn et al., 2009], but overall results from GWAS meta-analyses have been disappointing
[Ripke et al., 2012; Hek et al., 2013], potentially due to complexity of the disease and hetero-
geneity of patient cohorts. GWAS and transcriptome studies are highly complementary in
that they provide unbiased and large scale investigation of DNA structural (single nucleotide
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polymorphisms (SNP) and other variants) and functional (RNA expression) changes across
conditions, although these two approaches are only beginning to be integrated [Kupfer et al.,
2011; Cristino et al., 2013].
Gene arrays allow for the unbiased quantification of expression (mRNA transcript lev-
els) for 10,000 to 20,000 genes simultaneously. Since gene transcript levels represent the
integrated output of many regulatory pathways, the study of all expressed genes provides
an indirect snapshot of cellular function under diverse conditions. For instance, using post-
mortem brain samples, this approach has implicated dysregulated BDNF, GABA, glutamate
and oligodendrocyte functions in MDD [Tripp et al., 2012; Klempan et al., 2007; Sequeira
et al., 2009; Choudary et al., 2005; Guilloux et al., 2011]. However, current studies are
still few, were performed in heterogeneous cohorts, and utilized early and rudimentary ver-
sions of gene arrays. Moreover, gene array studies are subject to similar limitations as early
GWA studies, in that large number of genes are tested in few subjects (n=10-100). Typical
analyses identify 1-10% of genes affected in the illness (differentially expressed genes), are
characterized by high rates of false discovery, and may be confounded by numerous clinical
(drug exposure, subtypes, duration, etc.), demographic (age, sex, race), technical parameters
(RNA integrity, brain pH, postmortem interval for brain collection), or other potential co-
segregating factors of unknown origin (See Kupfer et al., 2011 for discussion). Conditions of
postmortem brain collection also preclude the reliable identification of acute state-dependent
gene changes, but are appropriate for investigating stable long-term disease-related homeo-
static adaptations.
Gene coexpression studies offer complementary perspectives on gene changes in the con-
text of transcriptome studies. Here, two genes are defined as coexpressed in a dataset if their
patterns of expression are correlated across samples. Coexpression has been shown to re-
flect possible shared function between these genes, and may arise through multiple biological
pathways including cellular coexpression and common regulatory pathways (e.g., hormone
signaling, transcription factors) [Lee et al., 2004; Gaiteri et al., 2010]. Hence, coexpression
links have been used to build gene networks, and to identify communities, or modules, of
genes with shared functions [Dobrin et al., 2009; Elo et al., 2007]. Notably, by incorporating
multiple interactions among large number of genes, the study of gene coexpression networks
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provides an approach to tackle the complexity of biological changes occurring in complex
polygenic disorders [Gaiteri et al., 2010]. See Gaiteri et al., 2013 for a general review.
Concepts and methods for integrating functional (transcriptome) and structural (DNA
polymorphism GWA) studies of the molecular bases of complex neuropsychiatric disorders
such as MDD need to be developed to harness the potential of systematic large-scale molec-
ular and genetic investigations of the brain. Here, our central hypothesis states that stable
brain co-regulation modules identified through meta-analysis of multiple transcriptome stud-
ies may overlap with sets of genes and associated variants (SNPs) related to MDD. Based
on the continuum of pathological changes between MDD and other brain disorders [Sibille
and French, 2013] and co-morbidity with selected medical illnesses including cardiovascular
diseases and metabolic syndrome [Pan et al., 2012; Musselman et al., 1998], we also pre-
dicted that MDD coexpression modules may be enriched in genes identified by GWAS for
other psychiatric and brain disorders and potentially for medical illnesses related to depres-
sion, together identifying functionally-coherent gene sets implicated in MDD-related disease
processes.
3.2 MATERIALS AND METHODS
Figure 8 illustrates the meta-clustering and validation methods of the approach. In step I, we
identified 50 robust co-regulation modules in human brains by combining 11 transcriptome
datasets collected from several brain regions in different cohorts of subjects with MDD and
non-affected comparison subjects. Steps II and III were performed to identify MDD-related
gene modules, and exclude other gene modules linked to biological functions not related to
MDD. In step II, we collected different sets of genes located nearby SNPs identified by GWAS
for MDD, neuropsychiatric disorders, related traits, and for systemic diseases often associ-
ated with psychiatric disorders, and perform gene set analysis to identify MDD-related gene
module(s). In step III, we performed functional annotations of gene module members by us-
ing 2,334 gene sets collected from MSigDB (http://www.broadinstitute.org/gsea/msigdb/).
We also organized genes identified by SNPs in published GWAS into three categories (cancer
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studies, human body indices and unrelated diseases) and treated them as a non-MDD-related
negative control gene sets in step IV.
3.2.1 Transcriptome data sets
Eleven MDD microarray datasets generated in our lab were used here. Cohorts and brain ar-
eas investigated are listed in Table 3 and details were provided in [Wang et al., 2012b; Sibille
et al., 2004]. Among these studies, six used Affymetrix Human Genome U133 Plus 2.0
platforms (Affymetrix Inc., Santa Clara, CA), two used Affymetrix Human Genome U133A
platforms, and the remaining three used Human HT-12 arrays from Illumina (Illumina Inc,
San Diego, CA). For gene matching across studies, when multiple probes or probe sets match
to one gene symbol, we choose the probe set with the largest variation (largest interquartile
range; IQR) to represent the gene [Gentleman et al., 2005]. For preprocessing, data were
log-transformed (base 2). Non-expressed (small mean intensity) and non-informative (small
standard deviation) genes were filtered out. To perform such filtering for 11 studies simulta-
neously, we calculated the ranks of row means and row standard deviations of each gene in
each single study. The ranks were summed up across 11 studies and used as criteria to filter
out non-expressed and non-informative genes. Figure S8 provides a diagram and results of
the transcriptome dataset preprocessing procedures.
3.2.2 Meta-clustering of transcriptomic data to construct co-expression gene
modules
The 11 transcriptome studies were combined to construct co-expression gene modules using
a meta-clustering technique described below. Denote by Xgsk the gene expression intensity
of gene g, sample s and study k, and Xgk = (Xg1k, . . . , XgSk) the vector of gene expression
intensities of gene g and study k. Define the dissimilarity measure between gene i and
gene j for a given study k as d
(k)
i,j = 1 − |cor(Xik, Xjk)|, where cor(Xik, Xjk) is the Pearson
correlation of the two gene vectors. To combine the dissimilarity information of the K = 11
studies, we took mean of meta-dissimilarity measure between gene i and gene j as d(gi, gj) =
Mean(d
(1)
ij , d
(2)
ij , . . . , d
(K)
ij ). Given the meta-dissimilarity measure, the Penalized K-medoids
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clustering algorithm was then applied to construct co-expression gene modules [Tseng, 2007].
The target function to be minimized by Penalized K-medoids is shown below:
L(C) =
G∑
i=1
∑
gi∈Ch
d(gi, gh) + λ · |S| (3.1)
where the clustering result C = (C1, . . . , CH , S) contains H non-overlapping gene clusters
(i.e. H gene modules C1, . . . , CH) and a set of scattered genes S that cannot be clustered
into any of the tight gene modules, gh denotes the medoid gene of cluster h such that
its average dissimilarity to all other genes in the cluster is minimal, |S| is the size of the
scattered gene set S and λ is a tuning parameter controlling tightness of detected gene
modules and the number of scattered genes discarded to S. The first term of the target
function L(C) calculates the total sum of within-cluster dispersion and is essentially the K-
medoids algorithm (an extended form of K-means using arbitrary non-Euclidean dissimilarity
measure). The second penalty term allows scattered genes not to be clustered into any gene
module. For example, if the distances of a gene gi to all cluster medoids are greater than
λ, minimizing L(C) will assign the gene into the scattered gene set S, instead of into any
gene cluster. Intuitively, smaller λ generates tighter clusters and allow more genes into
scattered gene set S. The rationale for the choice of this approach was based on finding in
the literature, where comparative studies show that many genes are not tightly co-expressed
with any gene clusters and methods that allow scattered gene assignment generates tighter
gene modules that are biologically more informative [Thalamuthu et al., 2006].
3.2.3 Parameter selection and evaluation of meta-clustering
We tested different parameter settings of H = 50 or 100 modules, and λ such that β =
0%, 25% or 50% of genes are left to scattered gene set S. In all performance of the 2× 3 = 6
combinations for the meta-clustering method, a biological validation was performed using bi-
ological pathway information. We searched ten keywords (“GABA”, “Insulin”, “Diabetes”,
“Immune”, “Thyroid”, “Estrogen”, “Depression”, “Alzheimer”, “Parkinson” and “Hunting-
ton”) in MSigDB and finally obtained 98 MDD-related pathways. In each clustering result,
Fishers exact test was applied to each module to correlate with each of the 98 MDD-related
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pathways and eight GWAS gene lists and the p-values were generated. Wilcoxon signed rank
test was used to compare any pair of clustering results (from different parameter setting) so
that the best parameter setting could be determined.
3.2.4 Evaluation of robustness and stability of meta-clustering method
To evaluate the robustness of the meta-clustering results, we used the Adjusted Rand Index
(ARI) as a measurement of consistency between two clustering results [Hubert and Arabie,
1985]. We randomly selected a subset of studies from 11 MDD studies and calculated the
ARI to assess the similarity of the obtained modules compared to those obtained using
the 11 MDD studies. The procedure was repeated 100 times and the averaged ARI was
calculated. For the stability of meta-clustering method, the mean and standard deviation
of ARIs were obtained by bootstrapping method [Efron, 1979], where the 11 MDD studies
were bootstrapped 100 times.
3.2.5 Genome-wide association studies (GWAS)-related gene categories
Eight neuropsychiatry-related candidate gene lists and three gene lists from presumably
unrelated disorders or traits were identified from relevant GWAS. Individual genes were
identified by the presence of GWAS significant SNPs within a given nucleotide distance from
the coding region of that gene.
I. The first gene list was obtained from a published GWAS for neuroticism [van den Oord
et al., 2008]. Neuroticism is a personality trait that reflects a tendency toward negative
mood states, and that is linked to several internalizing psychiatric conditions. That
GWAS involved 1,227 healthy individuals with self-report of no diagnosis of or treatment
for schizophrenia, schizoaffective disorder or bipolar disorder and personality measures
of neuroticism. In van den Oord et al. [2008],Genotyped data were generated from
Affymetrix GeneChip Human Mapping 500K using BRLMM algorithm. 449 SNPs were
selected by p value less than 0.001, and 155 genes were identified to have contained one
or more selected SNPs in the 10 kilobases (kb) up- and down-stream extension of the
coding regions.
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II. The second gene list was obtained from the MDD 2000+ project that included a meta-
analysis of MDD studies with 2,431 MDD cases and 3,673 controls [Wray et al., 2010].
Similarly, 532 SNPs with p value less than 0.001 were mapped to gene coding regions
(including 10kb upstream and downstream regions) and 159 genes were identified.
III. The third gene list was obtained from a mega-analysis of GWAS for MDD [Ripke et al.,
2012]. The associated 202 SNPs’ p values were less than 10−5 and 52 genes were identified
using the University of California Santa Cruz Human Genome Browser, hg18 assembly
(UCSC hg18) with build 36.3. Gene symbols from the build version 36.3 in the National
Center for Biotechnology Information (NCBI) database were used.
IV. The fourth candidate gene list was obtained from a mega-GWAS of bipolar disease which
contained 7,481 patients and 9,250 controls [Sklar et al., 2011]. 6,887 SNPs were iden-
tified when p value less than 0.001. By mapping the SNPs to gene coding region using
SNPnexus software (http://snp-nexus.org/), 602 genes were obtained.
V. For the fifth to eighth gene lists, we interrogated the Catalog of Published Genome-
Wide Association Studies [Hindorff et al., 2009] (http://www.genome.gov/gwastudies/).
The database (as of 01/31/13; time of the latest data analysis update) contained 10,183
entries of disease- or trait-associated SNPs with p values smaller than 10−5 in 1,491
GWAS studies. We manually regrouped the disorders and traits into 4 categories: (1)
all MDD-related studies, (2) all neuropsychiatric disorder studies, (3) all neurological
disorder and brain phenotypes studies, (4) all medical illnesses sharing increased risk
with MDD. Note that list #3 was included in list #2 and list #2 was included in list
#1. Lists #4 is independent and non-overlapping with others. The associated four gene
lists were then compiled, and genes were uniquely included when the mapped SNP was
within the gene region including a 100 kb upstream and downstream.
VI. As negative controls, we identified in the catalog of published GWAS three gene sets
presumably not related to psychiatric diseases: (a) 65 publications (270 genes) of cancer
GWAS studies; (b) 42 publications (459 genes) of human body indices GWAS studies
(HBI: genetic phenotypes for human, for example: height, weight, eye color, etc.); and
(c) 33 publications (187 genes) of GWAS studies for common disease traits not related
to brain function or major mental illnesses.
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3.2.6 Meta-analysis to aggregate evidence of association of each module with
the GWAS gene lists
We performed Fisher’s exact test to examine the significance of the association of genes within
each co-expresion module with individual GWAS-derived gene lists, using the 10,000 genes
evaluated in transcriptome meta-analysis (Figure S8) as background. To assess statistical
significance of association of each identified module from meta-clustering method, we applied
the Stouffer’s method to combine the p values obtained from Fisher’s exact test of the
association between gene modules and eight GWAS gene sets. The Stouffer’s statistics
TStouffer =
Σki=1φ
−1(Pi)√
k
where φ the cumulative distribution function of a standard normal
distribution [Stouffer, 1949]. The p values were assessed for each of the 50 modules by
conventional permutation analysis (B=500).
3.2.7 Pathway analysis and enrichment analysis of GWAS gene lists
For biological association, 2,334 annotated pathways (gene sets) were obtained from MSigDB
(www.broadinstitute.org/gsea/msigdb/), which consists of 880 canonical pathways (217 Bio-
carta gene sets, 180 KEGG gene sets, 430 Reactome gene sets and 53 other gene sets) and
1,454 pathways from Gene Ontology (GO). For each of the gene module, gene set (pathway)
analysis was performed for the 2,334 pathways and 11 GWAS gene lists (including 3 negative
controls). Fisher’s exact test was performed to assess the biological association between gene
modules and given gene sets. To account for multiple comparisons, Benjamini and Hochberg
procedure was used to control the false discovery rate (FDR).
3.3 RESULTS
3.3.1 Data preprocessing and parameter determination
16,443 genes were retained after gene matching across the 11 studies. Cohorts 10 and 11
were from older platforms with fewer probesets representing only 12,703 genes (Figure S8).
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In order to minimize the loss of information from gene matching, we allowed 20% missing
values during matching, i.e., we kept genes with at least 9 existing measurements out of
11 studies. 13,500 genes were retained after filtering out lower sum rankings of median
row means, and 10,000 genes after further filtering out lower sum rankings of median row
standard deviations. We then tested different parameter settings for the number of modules
(H = 50 or 100), and genes (tuned the λ values for controlling tightness of detected gene
modules and the number of scattered genes set) for β =0%, 25% or 50% of genes left out of
the gene set S. In all tests of the Penalized K-medoids meta-clustering method (2 × 3 = 6
combinations), we performed a validation by biological pathway information content. For all
clustering results, Fisher’s exact test was applied to each module to correlate with each of the
98 MDD pathways and eight GWAS gene lists described in the methods, and p values were
generated. The Wilcoxon signed rank test was used to compare any pair of clustering results
(from different parameter settings) so that the best parameter setting could be determined.
The result shows that there was no significant difference (by Wilcoxon signed rank test)
between H = 50 and H = 100 cluster except β = 0% (i.e., keep all genes), and the minimum
p value of gene set analysis in H = 50 was always lower than that in H = 100 in β = 25%
and β = 50%. It is reasonable to set the noise level in clustering method because noise will
increase if we combined more studies. We chose H = 50 because the mean of the − log 10(p)
in 50 modules (3.2793) was higher than 100 modules (3.0224) in β = 25%, and the mean of
the − log 10(p) in 50 modules (3.1896) was higher than 100 modules (3.0588) in β = 50%. 50
modules also provide adequate number and sizes of gene modules for the purpose of further
analyses. Given H = 50, we compared the performance with different choices of β. β = 25%
performed better than β = 0% (p= 0.0004 using Wilcoxon signed rank test), and there was
no significant difference between β = 25% and β = 50% (p= 0.0856). Finally, we selected
H = 50 and tuning parameter λ such that β = 25% genes are left to scattered gene set S
throughout this paper.
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3.3.2 Construction of 50 meta-modules from 11 MDD studies
Using the parameters determined above, we performed a meta-analysis of module gene mem-
bership to identify the top 50 conserved meta-modules across 11 MDD transcriptome studies.
A total of 10,000 genes were clustered using the Penalized K-Medoid method. 7,797 genes
were clustered into K = 50 modules and 2,203 genes (β =∼ 25%) were determined as scat-
tered genes with no conserved expression pattern. We performed subsampling and bootstrap
methods to assess the stability of the resulting clusters. Subsets (n = 8, 9 or 10) of the 11
studies were randomly selected and the meta-clustering procedure was similarly applied. The
resulting meta-modules were compared with the meta-modules obtained using the 11 MDD
studies using adjusted Rand index (ARI= 0.47, 0.52 and 0.63 for n = 8, 9, 10). We also
generated bootstrapped samples in each study and repeated the meta-clustering procedures.
Comparison of meta-modules generated from bootstrapped samples with original samples
generated an average ARI= 0.45 (standard deviation 0.025) in 100 repeated bootstrapping
simulations. In the literature, an ARI of ∼0.5 is interpreted as reproducible clustering re-
sult [Thalamuthu et al., 2006], hence demonstrating good stability under data perturbation
(subsampling and bootstrapping) for the 50 meta-modules obtained by combining 11 studies.
3.3.3 Association of meta-modules with eleven GWAS-determined gene lists
We examined association of the 50 meta-modules with the eight GWAS gene lists using
Fisher’s exact test. The results are shown in Supplementary Table S8. Module #35 is found
to have significant associations (p<0.05) with the six psychiatric disorder related GWAS
gene sets (p= 0.03 for the neuroticism GWAS gene set; p= 0.03 for MDD 2000+ project;
p=0.0001 for Mega-GWAS MDD; p=0.03 for Mega-GWAS of bipolar disorder; p=0.008 for
the catalog of GWAS studies of neuropsychiatric disorder; p=0.03 for the catalog of GWAS
studies of neurological disorders and brain phenotypes) and two studies with borderline p
values (p=0.05 for the catalog of MDD-related GWAS studies; p=0.05 for the catalog of
GWAS studies of Medical illnesses sharing clinical risk with MDD). We combined the p
values of the eight psychiatric disorder related GWAS gene sets by Stouffer meta-analysis
method. The p value of module #35 is 4×10−5 after the permutation test. In contrast, there
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was no association with cancer (p=1.00), human body indices (p=0.18) and other control
diseases (p=0.46) GWAS gene sets. Figure 9(a) shows the heatmaps of log-transformed
p values from pathway analysis for the 50 modules obtained from MDD cases and controls
combined analysis and 50 modules obtained from controls only analysis. It shows that module
#35 (highlighted in green) from the combined cases and controls analysis is enriched in genes
contained in six MDD-related GWAS gene sets, but not enriched in the three negative control
GWAS gene sets. None of the other 49 modules showed such consistent pattern.
3.3.4 Pathway analysis of meta-module #35
Many GWAS-hit genes (overlapping genes between 88 genes in module #35 and 8 GWAS
lists) were related to synaptic function, signal transduction, and neuronal development and
morphogenesis (Table 4). Of specific interest, and consistent with current hypotheses for the
molecular pathology of MDD, was the inclusion of brain-derived neurotrophic factor (BDNF )
and other factors implicated in development and maintenance of cell circuits (Ephrin recep-
tors EPHA3 and EPHA5 ; Netrin G1 (NTNG1 ); SLITRK3 and SLITRK5 ), of GABA-
related genes (GABBR2, GABRA4 and CALB1 ), glutamate receptors (GRM1 and GRM7 )
and other signaling neuropeptides previously implicated in mechanisms of psychiatric disor-
ders [reelin (RELN ) and gastrin-releasing peptide (GRP)]. Together, these results suggest
that module #35 may include multiple components of functionally-relevant local cell circuits
(Table 5)
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Figure 8: Overall analytical strategy.
In step I, 50 co-regulation modules were generated using meta-clustering of gene clusters
identified by the penalized K-medoids method across 11 transcriptome MDD and matched
controls studies. In step II modules enriched from most of selected GWAS studies related
to MDD, neuropsychiatric disorder and traits, including systemic disease linked to psychi-
atric disorders were identified. In step III, the biological functions represented by genes
included in each module were defined by pathway analysis from 2,334 gene sets of MSigDB
(www.broadinstitute.org/gsea/msigdb). In step IV, SNPs from the Catalog of GWAS were
organized into three categories: cancer GWAS, human body indices GWAS and GWAS for
common diseases and medial illnesses unrelated to MDD or other brain function. Three
additional categories were defined as non-MDD-related negative control gene sets. (Note: In
order to have better performance of heatmap in module #35, we first performed the hier-
archical clustering with complete agglomeration method to aggregated samples with similar
expression among all 88 genes, and the genes were sorted by the correlation from high to
low of selected gene in the top)
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Table 3: Description of cohorts in 11 MDD microarray platforms
Cohort Region Code Platform # of probes # of genes # of subjects
1 ACC MD1 ACC
Affymetrix
40,610 19,466 32Human Genome
U133 Plus 2.0
2 AMY MD1 AMY
Affymetrix
40,610 19,621 28Human Genome
U133 Plus 2.0
3 ACC MD2 ACC
Illumina
48,803 25,159 20HumanHT 12
(v3)
4 ACC MD3 ACC
Illumina
48,803 25,159 50HumanHT 12
(v3)
5 AMY MD3 AMY
Affymetrix
48,803 25,159 42HumanHT 12
(v3)
6 ACC BA25 F
Affymetrix
53,596 19,572 26Human Genome
U133 Plus 2.0
7 ACC BA25 M
Affymetrix
53,596 19,572 26Human Genome
U133 Plus 2.0
8 DLPFC BA9 F
Affymetrix
53,596 19,572 32Human Genome
U133 Plus 2.0
9 DLPFC BA9 M
Affymetrix
53,596 19,572 28Human Genome
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(a) MDD cases and matched controls (b) Controls only
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Figure 9: Consistent association of genes in module #35 with MDD-related gene categories.
(a) Heatmap of log10-transformed p values from Fisher’s exact test for 50 modules obtained from MDD cases and matched
controls and 8 MDD related GWAS and 3 negative controls. (b) Heatmap of log10-transformed p values from Fisher’s exact
test for 50 modules obtained from controls and 8 MDD related GWAS and 3 negative controls. The green rectangle identifies
module #35.
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Table 4: Functional groups of 88 genes in module #35
Functional groups Gene Symbols
Transmembrane cellular
CLSTN2, SYT4, LRRC8B, GPR6, TMEM158
localization
ST8SIA3, GABBR2, NRN1, ST6GALNAC5
GLT8D2, MPPE1, GNPTAB, PVRL3, SLC35B4
SLC35F3, KCNG3, SLC30A9, PTGER4, CYP46A1
GABRA4, UST, LOC646627, NTNG1, TMEM200A
TMEM70, RFTN1, GRM1, TMEM132D, KCNV1
EPHA3, CDH12, EPHA5, BEAN, SLITRK3
FREM3, GRM7, CD82, SLITRK5, VLDLR
Neuronal development BDNF, SLITRK3, RPGRIP1L, MAEL, NTNG1,
and morphogenesis RELN, LAMB1, SLITRK5, MYCBP2d
GABA and glutamate GRM1, GRM7, GABBR2, GABRA4
Cell adhesion
PPFIA2, CDH12, FREM3, CLSTN2, PVRL3,
RELN, LAMB1
Transcription regulation
EGR3, DACH1, HDAC9, ATOH7, SLC30A9
ATF7IP2, ZNF436, MYCBP2
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Table 5: Top 15 enriched pathways in module #35
Pathways P value
METABOTROPIC GLUTAMATE GABA B LIKE RECEPTOR ACTIVITY 0.0003
REACTOME CLASS C3 METABOTROPIC GLUTAMATE PHEROMONE RECEPTORS 0.0005
G PROTEIN SIGNALING COUPLED TO CAMP NUCLEOTIDE SECOND MESSENGER 0.002
CAMP MEDIATED SIGNALING 0.002
GLUTAMATE RECEPTOR ACTIVITY 0.003
G PROTEIN COUPLED RECEPTOR PROTEIN SIGNALING PATHWAY 0.003
G PROTEIN SIGNALING COUPLED TO CYCLIC NUCLEOTIDE SECOND MESSENGER 0.008
CYCLIC NUCLEOTIDE MEDIATED SIGNALING 0.01
NEUROPEPTIDE HORMONE ACTIVITY 0.015
REACTOME GPCR LIGAND BINDING 0.02
KEGG NEUROACTIVE LIGAND RECEPTOR INTERACTION 0.03
G PROTEIN COUPLED RECEPTOR ACTIVITY 0.03
SECOND MESSENGER MEDIATED SIGNALING 0.04
HORMONE ACTIVITY 0.04
REACTOME EICOSANOID LIGAND BINDING RECEPTORS 0.04
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3.3.5 Control studies
To demonstrate the improvement of meta-clustering versus single study clustering, we com-
pared the histograms of p values obtained under those different conditions. In Figure 10 ,
the histogram of the minus log-transformed p values of the Stouffer statistic was first plotted
for the 50 meta-modules obtained from the case and control combined analysis. Module
#35 with 88 genes is shown to have an aggregated minus log-transformed p value at 4.4 (i.e.
p= 4 × 10−5). We then applied the penalized K-medoid method with the same parameter
setting (K = 50 clusters and 25% of scattered genes) for each single study. The 11 single
study histograms of Stouffer p values showed overall much weaker statistical significance
than for module #35. Particularly, none of the 550 modules from 11 single study cluster
analysis was enriched (p value threshold 0.05) in more than three GWAS results (Figure 10).
Only four out of the 550 modules had more than 14 genes ( 15% of the 88 genes; indicated by
blue arrows in Figure 10) that overlapped with module #35. Hence, the meta-clustering ap-
proach efficiently combined weak signals in single studies to identify a stable and biologically
more meaningful gene module. In other words, module #35 would not have been discovered
without combining 11 studies.
We next tested the meta-clustering approach using transcriptomic data from control
subjects only (i.e., removing all MDD subjects) from the same 11 studies. Out of the
50 modules generated, no module was enriched in more than two GWAS studies (p value
threshold 0.05) among the eight GWAS results (see heatmap in Figure 9(b)), indicating that
the inclusion of the MDD cases was necessary for the detection of significant module/GWAS
overlap (i.e., module #35). We also tested the meta-clustering approach using transcriptomic
data from MDD subjects only (i.e., removing all control subjects) from the same 11 studies.
Among the 50 modules generated, one module (module #15 with 169 genes) was enriched
in six out of the 8 GWAS categories (p<0.05) but notably not in the gene set corresponding
to the Mega GWAS MDD (p=0.29) and to MDD-related studies (p=0.43) in the catalog
of GWAS (data not shown here). This module only has 3 genes overlapped with the 88
genes (ST8SIA3, GRM7 and MYCBP2 ) of module #35 extracted from the case and control
combined analysis. Pathway analysis of this module indicated an over-representation of
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signal transduction pathways. Overall, the statistical significance of results using MDD data
only was lower and potentially inconclusive (i.e., at background noise level)
Together these results indicate that combining MDD and control subjects in meta-
clustering approaches increased the significance and robustness of the results, as demon-
strated by the identification of the tight module of 88 genes with high relevance to current
biological knowledge about MDD.
Module #35 
(88 genes) 
Module #30 
(16 overlap genes) 
Module #32 
(18 overlap genes) 
Module #17 
(23 overlap genes) 
Module #31 
(17 overlap genes) 
Figure 10: Histograms of the − log10(p) of the Stouffer statistic from 50 modules
of meta-analysis of 11 MDD studies and each single study.
Module #35 with 88 genes (red arrow and double-cross) have largest − log10 transformed p
value of Stouffer’s statistic 4.4. The other four blue arrows and double crosses indicated that
these four modules in all single studies have more than 14 (15% of the 88 genes in module
#35) overlapped with module #35. See detailed description in text.
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3.4 DISCUSSION
Using methods we developed to identify conserved co-expression modules across transcrip-
tome datasets, we report the identification of a module consisting of 88 genes that is sig-
nificantly enriched in genetic variants located nearby genes otherwise associated with major
depression and related phenotypes. The finding of a significant intersection of two un-
biased large-scale approaches (transcriptome and GWAS) provide robust evidence for the
putative recruitment and contribution to molecular and cellular mechanisms of MDD of a
biological module that is formed by the identified gene set. This module includes numerous
genes encoding proteins implicated in neuronal signaling and structure, including glutamate
metabotropic receptors (GRM1, GRM7 ), GABA-related proteins (GABRA2, GABRA4,
CALB1 ), and neurotrophic and development-related molecules [e.g., BDNF, reelin (RELN ),
Ephrin receptors (EPHA3, EPHA5 )]. These findings are consistent with current hypotheses
of molecular mechanisms of MDD, notably with the GABA, glutamate and neurotrophic hy-
potheses of depression [Sibille and French, 2013; Luscher et al., 2010; Belmaker and Agam,
2008; Nestler et al., 2002; Duman and Monteggia, 2006]. This biological “internal valida-
tion”, combined with control studies showing that these results could not be achieved using
single studies (due to weak signal) demonstrates that integrating transcriptome data, gene
co-expression modules and GWAS results can provide a novel and powerful framework to im-
prove understanding of MDD and other complex neuropsychiatric disorders. This approach
also provided here a set of putative interacting molecular partners, potentially reflecting a
core biological module that is recruited and implicated in biological mechanisms of MDD.
The meta-clustering approach in this paper has the following novelty and advantages.
(1) Meta-analysis : Our result indicated that a meta-analysis of gene clustering to combine
multiple transcriptome studies can identify more accurate and robust gene modules, since
the same clustering method applied to single studies did not lead to the identification of any
significant and/or neuropsychiatry-related module. (2) Cluster analysis allowing “scattered
genes”: Gene co-expression modules were identified by penalized K-medoid. This clustering
technique searches for tight gene modules and allows some genes to be scattered. This means
that they are not included in the final set of modules/clusters, unlike other traditional clus-
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tering methods, such as hierarchical clustering, K-means or self-organizing maps that force
all genes into clusters. In genomic applications, it was shown that allowing scattered genes
can improve clustering performance with better biological knowledge discovery [Thalamuthu
et al., 2006]. (3) Integration and validation with external databases : Integration with rich
GWAS and pathway knowledge databases for biological and disease interpretation identified
a robust module with 88 genes that is consistent with current knowledge about depression,
hence providing some level of “internal control” for the methods. (4) Case and control
combined co-expression analysis : We showed that the combination of case and control co-
expression analysis was necessary to reveal the co-expression perturbation originating from
the disease. This is an important observation as co-expression studies rely on subtle differ-
ences in expression patterns compared to differential expression between two groups. Hence
disease-related co-expression modules could have been predicted to be unique to the disease
groups and “diluted” when combined with control data. However, we show that the opposite
is true, resulting in increased power in the combined dataset. For technical validation, we
have performed the following: First, we fine-tuned the parameters to be used in the final
meta-clustering analysis (i.e., number of modules, percentage of allowed scattered genes in
penalized K-medoid method) and tested those parameters in three studies using “surrogate”
information, i.e., gene families and biological pathways broadly associated with psychiatric
disorders (See Methods section). Second, subsampling and bootstrap simulation were ap-
plied to investigate the stability of the identified gene modules. Third, three non-psychiatric
related GWAS gene sets (cancer, human body indexes and disease traits unrelated to mental
functions) served as negative controls.
Co-expression links between genes are inferred from microarray expression studies but
do not refer to any specific mechanism underlying these correlations. In fact, any mecha-
nism that synchronously regulates transcription of multiple genes may potentially generate
co-expression relationships, including biophysical sources (e.g., transcription factors, spatial
configuration of chromosomes, mRNA degradation, miRNA or other upstream regulation,
histone acetylation and methylation patterns), technical effects (e.g., batch processing, RNA
quality), cell biological sources (e.g., cellular admixture of the sampled tissue, brain region),
and importantly synchronized activities across cells under homeostatic equilibria correspond-
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ing to “control” states, trait conditions, or chronic disease states for instance. Here, results
in module #35 identify a set of genes whose products are distributed across cell types, cel-
lular compartments and biological processes (Tables 4-5) that together contribute to various
and potentially complementary biological processes, and whose collective function may be
related to pathological processes implicated in depression.
The biological content of the identified gene module is notable in that it brings together 
multiple genes that have been otherwise associated with depression and other neuropsychi- 
atric disorders through multiple studies both in humans and animal models, in addition to the 
genetic links (i.e., GWAS) that were used here to identify them. Such commonly associated 
genes include those coding for BDNF, and GABA- and glutamate receptors, for instance 
[Tripp et al., 2012; Klempan et al., 2007; Sequeira et al., 2009; Choudary et al., 2005; Guilloux 
et al., 2011]. Prior findings often refer to differential expression, e.g. reduced BDNF [Guilloux 
et al., 2011], or reduction in calbindin (CALB1 ) positive GABA neurons [Rajkowska et al., 
2006]. Here, reports of conserved co-regulated patterns between these genes suggests that 
changes in the fine-tuning and synchronization of the function of these gene products across 
cells and pathways may contribute to pathophysiological mechanisms related to brain 
dysfunction in MDD. The fact that these results implicate genes that are likely to be expressed 
across cell types or to regulate ensembles of cells (i.e. neurotrophic and neuro-maintenance 
factors) is consistent with mechanisms expected for polygenic com- plex disorders. Moreover, 
the identification of module #35 through overlap with GWAS findings for traits (i.e., 
neuroticism) and other neuropsychiatric disorders (Figure 9) also suggests that those genes 
may participate in basic cellular functions that are implicated in a continuum of biological 
states (i.e., from normal to disease brain functions), consistent with a dimensional 
understanding of biological mechanisms of brain disorders. The fact that borderline 
significance in gene overlap was also observed for categories of disorders sharing clinical risk 
with MDD (i.e., cardiovascular diseases, inflammation and metabolic syndrome) suggest that 
the same gene sets may also contribute to dysfunctions in peripheral organs through 
pleiotropic functions of common genes, hence providing putative biological links for the 
clinical and symptom co-morbidity. Follow-up studies of co-expression patterns obtained in 
datasets across these disorders may be necessary to further investigate these interesting hints.
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So while these studies provide insight into the biology of complex disorders, one may rea-
sonably ask how they may contribute to the generation of novel hypotheses and predictions.
Two directions are worth mentioning. First, for the purpose of therapeutic development and
target identification, the application of graph theory and other network analysis may help
identify critical genes within the identified module or upstream factors, as potential medi-
ators of the function of this module in disease state. Preliminary analyses of the network
properties of module #35 did not provide clear insight into hub genes or other parameters
of interest (data not shown); however these studies may be confounded by circular analyses
within the same datasets. Thus, testing these hypotheses in other large-scale disease related
datasets are needed to, firstly, refine gene membership into the identified module, in view of
the reasonable and significant conservation of module structure across datasets, although not
to absolute levels; and, secondly, to identify key network nodes with conserved cross-studies
functions, as potential targets to modulate the functional outcome of the identified gene
module. Finally, an additional and important outcome of these studies is that they provide
a focused set of genes, which can be used for follow-up genetic association studies, hence
potentially mitigating the problem of reduced statistical power of large scale genome-wide
studies.
There are several limitations to this study. First, there is a bias when selecting gene sets
from the catalog of published GWAS results since the targeted markers (SNPs) are updated
every six months, and many more SNPs were reported in the past five years when GWAS
have achieved greater sample size (including studies with more than 10,000 participants)
and detection of markers with very small effect size. However, large sample sizes will also
introduce a bias towards false positive markers. A related limitation is that the choice of
markers (or gene) was based on fixed and arbitrary thresholds (i.e., p value and genomic
distance). Moreover, we used only a small fraction of the datasets and pre-defined path-
ways related to psychiatric disease to decide on the number of clusters and sets of scattered
genes during the method development phase, so the result of the clustering approaches may
still show some instability and may vary based on different numbers of clusters and ap-
plied thresholds. Indeed, although we performed extensive validation analyses to select the
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clustering parameters and increase stability of modules, the 88 genes in module #35 will in-
evitably vary slightly under additional data perturbation (e.g., when adding additional MDD
or related studies). An additional limitation is that generating gene co-expression modules
using cluster analyses is known to be sensitive to small data perturbation. To mitigate these
effects, we combined multiple studies and concentrated on tight modules by leaving out scat-
tered genes. While this approach increased the power of the meta-clustering method, it also
meant combining datasets from different brain regions, hence potentially diluting the effects
of local co-regulation patterns that may be important for disease mechanisms. So these
results should be considered proof-of-concept, rather than experimentally and biologically
optimized. Finally, it is important to note that changes in gene co-expression are difficult
to confirm by independent measures. Indeed co-expression links rely on large sample size
and we previously showed that the sample-to-sample variability in array-based measures of
expression is typically lower than the variability obtained using alternate measures such as
quantitative PCR [Gaiteri et al., 2010], so the ultimate test of the added value of these
meta-co-expression studies will need to come from additional independent studies. Nonethe-
less, this study allowed the identification of a focused set of genes for use in future genetic
association studies, and together demonstrates the importance of integrating transcriptome
data, gene co-expression modules and GWAS results, paving the way for novel and com-
plementary approaches to investigate the molecular pathology of MDD and other complex
brain disorders.
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4.0 THE ANALYSIS OF FAMILY-BASED SEQUENCE DATA
4.1 INTRODUCTION
Next generation sequencing is an advanced technology which can identify common variants
(minor allele frequency > 5%) as well as those done by typical GWAS, and systematically
search for rare variants. Recently, the 1,000 Genome Project has provided characterization
of human genome sequence variation for us to understand the relationship between genotype
and phenotype [Abecasis et al., 2010]. Family-based sequencing studies have unique advan-
tages and strengths in controlling population stratification, studying parent-of-origin effects,
identifying rare causal variants and detecting de novo mutations [Ott et al., 2011; Laird and
Lange, 2006; Ng et al., 2010a; Ng et al., 2009; Ng et al., 2010b; Zhu et al., 2010]. Sequencing
has also been proven successful in studying Mendelian disorders in families [Ng et al., 2009;
Roach et al., 2010; Boileau et al., 2012]. Numerous family-based sequencing projects (often
in the design of large number of trios/nuclear families or a mixture of unrelated individuals
and small families) have been carried out or launched to study complex diseases [Sanders
et al., 2012; Neale et al., 2012; ORoak et al., 2012; Boomsma et al., 2013; Pilia et al., 2006].
Many ongoing sequencing projects include nuclear families (two parents with one or more
offspring) or multi-generational families. Chen et al. [2013] proposed a method of genotype
calling by considering family structure in trios that can achieve more accurate genotype
calls in great amounts as compared with the one without considering the family structure
(reduces genotype calling error rate by 50%). However, to our knowledge, there is no ex-
isting method that jointly models family constraints and LD patterns in complex pedigree
(nuclear and extended families). Existing approaches include methods that focus on single
sites or methods that split pedigrees into trios or treat all sequenced samples as unrelated
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individuals. Among the few existing methods for genotype calling of family-based sequence
data, most methods consider family constraints at each marker [Li et al., 2012; Peng et al.,
2013].
In this chapter, we described a novel method and developed a software which called
“FamLDCaller” (Genotype calling method incorporated by LD and family structure. We
used “FLDC” for abbreviation) for genotype calling and phasing in nuclear and extend fam-
ilies. Firstly, we extend the current method from analyzing trios to nuclear family or family
with multi-generations in a computationally efficient manner. Here we focus on developing
the procedure by looping over all possible parent-offspring trios to update the probability
of observed genotype given the true genotype simultaneously, which is a pivotal step in
the hidden Markov model (HMM). Through two simulated studies, which are with/wothout
alignment and experimental errors. We evaluate the performance by using the genotype error
calling rate and phasing error (as haplotypes are provided), and we show that incorporating
more offspring within family (or complex family with multiple generations) can have more
accurate genotype calls than trios only, especially in low to modest depth in sequencing data.
Secondly, we extend the method to analyze a small number of samples using the external
reference panels. This is motivated by many pilot projects, which often include a limited
number of samples (e.g. one or two trio) and LD information is not available in the study
population. External reference panels (e.g. the 1,000 Genome Project) will be useful in this
scenario to facilitate genotype calling and phasing if the LD pattern in the study population
is well captured. Through both simulated and real studies, we show that our methods out-
perform the existing methods that do not use LD information or ignore the complex family
constraints.
4.2 METHODS
4.2.1 Describing chromosomes as imperfect mosaics
Li and Stephens [2003] indicated that the haplotypes of each individual can be described as
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imperfect mosaics of other haplotypes in the sample of using hidden Markov model (HMM);
in specific, unrelated samples for same ethnicity are always sharing short stretch of the 
chromosomes, so each samples is a “mosaic” of haplotypes. And this approach has been 
successfully applied to genotype imputation and haplotype reconstruction [Li et al., 2010; 
Marchini et al., 2007; Scheet and Stephens, 2006]. This approach has also been used in 
genotype calling for sequence data. In this section, we briefly review the HMM method for 
model unrelated samples for the sequence data. More details can be found in our early paper 
[Chen et al., 2013]. First, allele from individual haplotype was sampled from reference panels 
consistent with observed data at each position. Second, using HMM method to update the 
haplotype for each individual, and the pair of haplotypes can be described as an imperfect 
mosaic of other reference panels.
Suppose all markers are bi-allelic, the first step is to calculate P (Ri|Gi), the likelihood of
observed read Ri given an underlying true genotype Gi at position i for all candidate variant
sites. P (Ri|Gi) can be defined by the following formula by assuming independent errors:

P (Ri = B,E|Gi = {A,A})
=
∏
j (1− ej)I(bj=1)(13ej)
I(bj 6=1) for homozygous genotype A/A
P (Ri = B,E|Gi = {A,B})
=
∏
j{12(1− ej)I(bj=1)(13ej)
I(bj 6=1)
+1
2
(1− ej)I(bj=2)(13ej)
I(bj 6=1)} for heterozygous genotype A/B.
where B and E represent the vectors of base calls and corresponding error probabilities for
position i and allele j (j = 1: first allele and j = 2: second allele) in each subject (bj and ej
are corresponding elements of B and E). bj = 1 means the j-th allele in observed reads is
identical with the j-th allele from underlying true genotype and I is an indicator function.
We then define the probability the probability of an underlying true genotype Gi given
the mosaic state Si, P (Gi|Si). The function T (Si) was defined as the number of different
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alleles for genotype Gi. So P (Gi|Si) was defined by:

(1− εi)2 {T (Si) = 0 or T (Si) = 2} and T (Si) = T (Gi)
εi(1− εi) {T (Si) = 0 or T (Si) = 2} and |T (Si)− T (Gi)| = 1
ε2i {T (Si) = 0 or T (Si) = 2} and |T (Si)− T (Gi)| = 2
(1− εi)2 + ε2i T (Si) = 1 and T (Si) = T (Gi)
2εi(1− εi) T (Si) = 1 and T (Si) 6= T (Gi)
where εi is the cumulative effects of mutation and gene conversion (we called it mosaic error
rate here) at marker i. Then we can calculated the emission probability of P (Ri|Si) as:
P (Ri|Si) = ΣGiP (Ri|Gi)× P (Gi|Si) (4.1)
Finally the transition probability P (Si+1|Si) in the HMM was defined by:
P (Si+1 = (w, v)|Si = (x, y))
=

θ2i
H2
w 6= x and y 6= v
(1− θi)θi
N +
θ2i
H2
w 6= x and y = v or w = x and y 6= v
(1− θi)2 + 2(1− θi)θiH +
θ2i
H2
w = x and y = v
where θi is the mosaic transition rate from position i− 1 to position i, and H is the number
of haplotypes in the reference panel. Our goal is to calculate P (Gi|R), the probability of a
genotype at position i conditional on all sequence reads:
P (Gi|R) = ΣSiP (Gi|Si)× P (Si|R) (4.2)
by looping all possible state Si. Baum’s forward-backward algorithm was used to calculate
P (Si|R) and P (Gi|R) [Rabiner, 1989].
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4.2.2 Procedure for modeling nuclear family
Chen et al. [2013] proposed a strategy for parent-offspring trios with computationally efficient
modeling of LD and the constraint due to Mendelian inheritance. We extended their proposed
algorithm from analyzing trios to nuclear families by looping over all possible trios within
each family. Consistent with their paper, we denote Rfk, Rmk and Rck as the read data from
k-th possible trio within a nuclear family, Gfk, Gmk and Gck as the underlying true genotype
for the father, mother and child, and the genotype likelihood was denoted by P (Rfk|Gfk),
P (Rmk|Gmk) and P (Rck|Gck). The procedure for each iteration was described below:
I. At position i, we randomly select a child in family and corresponding parents, denoted
by R¯i1 = (Rf(i)1, Rm(i)1), Rc(i)1).
II. First update parental haplotypes by sampling a mosaic state Sf(i)1 for father, then emis-
sion probability can be written as P (R¯i1|Sf(i)1) =
∑
g P (R¯i1|Gf(i)1 = g) × P (Gf(i)1 =
g|Sf(i)1), and P (R¯i1|Gf(i)1 = g) = P (R¯i1, Gf(i)1 = g)P (Gf(i)1 = g) =
∑
gm
P (Rf(i)1|Gf(i)1 = g) ×
P (Rm(i)1|Gm(i)1 = gm) × P (Rc(i)1|Gc(i)1 = transmit(gf , gm)), where transmit(gf , gm) re-
turns the genotype for child conditional on ordered parental genotypes Gf and Gm.
III. Updates maternal haplotypes at position i conditional on the sampled genotype for the
first parent. P (R¯i1|Si1, Gf(i)1 = gf ) =
∑
g P (Rf(i)1|Gf(i)1 = gf ) × P (Rm(i)1|Gm(i)1 =
gm)× P (Rc(i)1|Gc(i)1 = transmit(gf , gm)).
IV. Randomly select second child (Rc(i)2) and corresponding parents updated from previous
trio loop, and repeat step I - step III until all children (Rc(i)k, k = 1, 2, . . . , nl where nl is
number of children in family l) are used in each family.
V. Update next family and repeat step I - step IV until all families are used.
Each round of updates generates a new ordered haplotypes for each family (can be unrelated
individual, parent-offspring trio, nuclear family or family with multiple generations), the
consensus haplotype was generated by assigning the most frequently sampled allele at each
position. Figure 11 illustrates the example of updating haplotypes for each iteration in a
nuclear family with three offspring. For each iteration, we randomly selected one offspring
to form a trio (“random” here means we try to avoid keep using first offspring to update
parents’ haplotype in each iteration), and update the haplotypes of parents and offspring
68
(step II. and III. of the procedure). We than randomly selected second offspring to form a
trio with parents’ haplotypes updated from previous step, repeated step II. and III. until
all possible trios were looped in each family. This method can also be applied to multi-
generational family in a similar manner by looping through all offspring in a random order
in each iteration.
4.2.3 Use of phased reference panels
Public reference panels (e.g. 1KG Project and HapMap Project) can provide extra LD
information for genotype calling and have been successful in facilitate imputation. For
genotyping sequence data, most existing software do not use the information from reference
panel. Our method and implementation can incorporate phased reference panels efficiently
into our genotype calling procedure. It has two advantages: 1) we will be able to call a small
number of sequenced families/individuals using LD information from a similar population
with phased haplotypes available; 2) the computation will be efficient because we don’t have
to call all individuals but only sequenced individuals. This approach is particularly useful
for sequencing studies with a small sample sizes.
4.2.4 Simulated data
In the first simulation scheme, we considered 80 nuclear families, and each family has two
founders and four offspring. To be realistic, we generated 12 regions with 1 Mb length of
haplotypes, and each region contains 10,000 haplotypes generated from a coalescent model
to mimicking the LD pattern, population demographic history and local recombination rates
of European ancestry samples [Schaffner et al., 2005]. We randomly sampled haplotypes
for founders in each family and simulate the Mendelian transmission for the haplotypes of
offspring. The short read were simulated by assuming depth at each site follows a Poisson
distribution and defined per-based sequencing error rate. Each sample was sequenced at
depth 2x, 6x and 10x by assuming per base error (denoted as “BE” in all Tables and Fig-
ures throughout this chapter) rate of 0.01 (Phread scaled base quality of Q20). In order to
compare with the “TrioCaller” software proposed by Chen et al. [2013], we considered the
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following procedure when calling genotypes in each nuclear family: we selected first child to
form into a trio and treated other three children as unrelated subjects (result from “Trio-
Caller”), and then included the second child into consideration at a time until all children
were used.
In the second simulation scheme, we further considered sequencing and alignment errors
using the 1000 Genome Project (1000GP) data. We simulated founders entire genomes by
randomly selecting a pair of haplotypes from the 1000GP CEU population (March 2012
Phase 1 release). For non-founders, we simulated cross-overs in the parental haplotypes
based on the genetic map in the HapMap data, and then generate offspring genotypes by
randomly selecting one haplotype from each parent. We then simulated paired-end 100bp
reads according to Poisson distribution on the genome, with a mean insertion size of 400bp
and a standard deviation of 50bp, and a sequencing error rate of 0.01 per base. We used
BWA to align simulated reads to the reference of hg19 and carried out standard procedure
for variant calling using Genome Analysis Toolkit (GATK) [McKenna et al., 2010] including
indel-realignment and base quality realignment. The list of known indels from 1000GP was
provided to GATK for re-alignment prior to variant calling in different depths 5x, 10x, 20x
and 30x with 3,005,070 sites on chromosome 1. There are five families, and each family has
14 members (see pedigree in Figure S9). We considered the simulation settings similar to
our first simulation scheme: we selected nuclear family (parents and three offspring) in each
big family, then we selected first child to form into a trio and treated another two children
as unrelated subjects, and included the second child into consideration at a time until all
children were used. In addition, we also selected complex family with three generations from
each big family.
Next, we investigate if the reference panels can help increase genotyping accuracy. We
designed a simulation study by considering 2, 3 and 4 parent-offspring trios with depth 2x,
6x and 10x with per-base error rate of 0.01(Q20). For reference panels, we considered 10,
20, 40 and 60 founders from 1000 genome project.
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4.3 EVALUATION CRITERIA
First, we evaluated the performance of genotype calls using genotype mismatch rate between
genotypes estimated by our proposed algorithm and surrogated gold standard genotypes
from simulated data, especially in heterozygous sites, which is more sensitive case in geno-
type accuracy. Second, we calculated the number of mismatched alleles between estimated
haplotypes by our proposed algorithm and haplotypes from simulated data to evaluate the
haplotyping accuracy. Third, we also evaluated the Mendelian error by calculating the num-
ber of mismatching alleles between each offspring and corresponding parents.
4.4 SIMULATION RESULTS
4.4.1 Overall performance of genotype accuracy
We evaluated the performance of our proposed algorithm for genotype calling method in sim-
ulation studies and real data analysis. We have two goals: (1) extended the existing method
for analyzing trio-based data sets to handle complex family with multiple offspring and/or
generations; (2) proposed a function to analyze a small number of family-based samples in-
corporating the external reference panels, such as subjects from 1,000 Genome Project. For
goal one, We first evaluated the genotype accuracy when adding more offspring in each fam-
ily. Figure 12 shows the mean of the genotype mismatch rate of heterozygous calls and SNP
with minor allele frequency (MAF) < 5% summarized from twelve simulated haplotypes. It
shows the clear pattern that adding more offspring per family can reduce the genotype mis-
match rate (see also Table 6), especially in low depth (2x). The genotype mismatch rate of
heterozygous calls can reduced from 4.5% to 4.38% to 4.18% to 3.94% when one, two, three
and all four offspring were considered, respectively. Sequencing depth also contributed to
genotype accuracy: as 80 trios and 240 unrelated samples were sequenced, the genotype mis-
match rates of heterozygous calls reduced from 4.48% to 0.875% to 0.257% as depth increase
from 2x to 6x to 10x. The advantage of our proposed method makes clear that adding more
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offspring can achieve more accurate genotype calls, especially at low sequencing depths. The
second simulation scheme considered alignment and experimental errors also target on the
first purpose. Table 7 shows the genotype mismatch rate of heterozygous calls. In general,
GATK has high genotype mismatch rate, especially with depth 5x (16.4%) and 10x (2.7%)
and our proposed method greatly outperform the results from GATK. When all three off-
spring were all considered in our algorithm, the genotyping errors of heterozygous SNPs
can reduced from 16.4% and 2.7% to 0.9% and 0.4% at 5x and 10x coverage, respectively.
Genotype mismatch rate will keep decreasing when adding more offspring when using our
proposed method, especially at low depth 5x. The genotype discordance error rate can be
reduced from 0.92% to 0.84% to 0.77% by considering one, two and three offspring in each
family at 5x coverage. Furthermore, Our proposed method can handle the complex family
structure (genotype mismatch rate are 0.86%, 0.37%, 0.24% and 0.25% at depths 5x, 10x,
20x and 30x, respectively)
4.4.2 Performance of haplotyping
Haplotype reconstruction plays an important role for follow-up analysis such as genotype im-
putation; and studying the population history. The phasing error rates were calculated by
the mean number of mismatched alleles between reconstructed haplotypes by using our pro-
posed algorithm and haplotypes from simulated data (we assumed the simulated haplotypes
was underlying truth). The first simulation results from twelve simulated haplotypes were
summarized in Figure 13 and Table 8. In summary, at low depth 2x, adding more offspring in
each family can keep reducing the genotype mismatch rate. For instance, the phasing error
rate can reduce 25% when all four offspring were taken into consideration compared with
trio-based (only considers one offspring). Similar to genotype accuracy, sequencing depth
contributed to phasing error rate, but our proposed algorithm still showing its advantage to
lower the phasing error when adding more offspring.
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4.4.3 Performance on Mendelian errors
Since our proposed method considered the family constraint (we considered trio at a time
within whole family structure), we can also lower the Mendelian errors. We calculated
the Mendelian errors by calculating the total number of Mendelian inconsistent genotypes
divided by the total number of offspring in simulated data set. In our first simulation study
without considering alignment and experimental errors, the mean number of Mendelian
errors of our proposed method when considering all four offspring compared with trio-based
method in simulated data can be dropped from 13.86 to 9.04, 3.74 to 2.37 and 1.42 to 0.63
at 2x, 6x and 10x coverage, respectively (see Figure 14 and Table 9). The second simulation
result was summarized in Table 10 which showed the mean number of Mendelian errors for
each offspring with considering alignment and experimental errors. As compared with the
results from GATK, our proposed method can reduce the mean number of Mendelian error
from 28212.6 and 6475.1 to 718.3 and 227.73 SNP at 5x and 10x coverage, respectively. In
addition, when adding more offspring into consideration, our algorithm can achieve lower
Mendelian errors, especially with low depth 5x: the mean number of Mendelian errors can
be reduced from 1118.1 to 962.2 to 718.3 when considering one, two and three offspring in
each family, respectively.
4.4.4 Performance of incorporating reference panels
Next, we proceed to evaluate the genotype mismatch rates, phasing errors and Mendelian
errors by incorporating external references when sequencing data with small sample sizes for
our second purpose (see the simulation results summarized in Figure 15 to Figure 17 and
Table 11 to Table 13). In summary, for limited number of sequencing data, our proposed
algorithm by incorporating external references can also provide the accurate genotypes, and
reduce the phasing errors and Mendelian errors. For example, the genotype mismatch rates
dropped from 7% to 4% to 2.8% to 2.4%; the phasing error rates dropped from 0.2% to 0.12%
to 0.08% to 0.07% and the mean number of Mendelian errors dropped from 5.92 to 3.21 to
1.92 to 1.46 when incorporating 10, 20, 40 and 60 founders from 1,000 Genome Project
for 2 sequenced trios at 2x coverage. Sequencing depth is also a key factor for genotype
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accuracy, and we found that increasing the number of external references (founders) can be
a good way to compensate the depth. For example, the genotype mismatch rate at coverage
2x incorporated by 60 founders is 2.4%, which is similar to the genotype mismatch rate at
coverage 6x incorporated by 10 founders (∼2%); the genotype mismatch rate at coverage
6x incorporated by 60 founders is 0.55%, which is similar to the genotype mismatch rate at
coverage 10x incorporated by 10 founders (0.056%).
4.5 PERFORMANCE ON REAL DATA
We applied our methods to an ongoing sequencing project, which has a total of 2,499 sample
and includes 623 families with an average depth 10X (unpublished data). We focused on
chromosome 20 and calculated the mismatch rate between the called genotypes from our
method and the available genotypes from DNA microarray chips. Then, we compared the
mismatch rate using our methods with that using other existing method BEAGLE [Browning
and Browning, 2009]. In summary, our method outperforms the results from BEAGLE.
For all SNPs, the genotype mismatch rate of BEAGLE and our method are 1.012 × 10−3
and 7.75 × 10−4; For heterozygous SNPs, the genotype mismatch rate of BEAGLE and
our method are 1.863 × 10−3 and 1.539 × 10−3. We will continue our investigation when
more sequence data are available. Specifically, we also investigated few small regions on
chromosome 20 using different states (100, 200 and 400), as a result, the genotype mismatch
rate for heterozygous calls can reduced from 1.53× 10−3 to 1.22× 10−3 to 1.04× 10−3 when
100, 200 and 400 states were used.
We also applied our method to the 1,000 Genomes Project on deep sequenced trios for our
second purpose to incorporate external panels when analyzing family-based sequencing data
with small sample size. There are two trios with one trio from CEU and the other from YRI.
These two trios have been genotyped on OMNI chip. For CEU trio, the genotype mismatch
rate are 1.483× 10−3 and 1.776× 10−3 for all and heterozygous SNPs, respectively; for YRI
trio, the genotype mismatch rate are 1.886× 10−3 and 2.345× 10−3 for all and heterozygous
SNPs, respectively.
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4.6 IMPLEMENTATION AND SOFTWARE AVAILABILITY
We have implemented our methods efficiently in a C++ program FamLDCaller, which is
available from http://genome.sph.umich.edu/wiki/FamLDCaller.
4.7 DISCUSSION
In this chapter, we proposed a computationally feasible algorithm to call genotypes more
accurately by considering multiple offspring in family-based next generation sequencing data
set. In the simulation studies, we showed our proposed algorithm can obtain more accurate
genotype calls, lower phasing errors and Mendelian errors compared with the result from
trios-based method. In each iteration of MCMC step, we updated each parent multiple times
by incorporating multiple offspring within each family. Our proposed method outperforms
the results from Genome Analysis Toolkit (GATK) proposed by McKenna et al. [2010],
which is the most popular tools for site discovery and generate genotype likelihoods for each
sample, but they did not consider the family structure, which plays an important role for
reducing genotyping error and Mendelian errors, especially for the data with low depth. In
addition, our proposed algorithm provides a function to incorporate the external panels from
1,000 genome project when analyzing small number of family-based NGS data set (e.x. 2 ∼
4 trios). With the high cost of NGS data set and such price still not affordable in many labs,
the only way is to sacrifice the sample sizes or depths with limited budget. Our proposed
method in the simulation study showed that we can achieve satisfying result by incorporating
more founders if possible and the performance was as well as the same data set with high
depth.
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Figure 11: Example of updating haplotypes for each iteration in one nuclear
family with three offspring.
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Figure 12: Genotype mismatch rate of heterozygous calls and SNPs with maf <
5% (Simulation I). C1: trios; C2: nuclear families of two offspring; C3: nuclear families
of three offspring and C4: nuclear families of four offspring.
Table 6: Genotype mismatch rate of heterozygous calls and SNPs with maf < 5% (Simu-
lation I)
2x 6x 10x
80 trios, 240 unrelated 0.0448 0.00875 0.00257
Heterozygous 80 nuclear families (twooffspring) , 160 unrelated 0.0438 0.00758 0.00203
calls 80 nuclear families (three offspring), 80 unrelated 0.0419 0.00643 0.00153
80 nuclear families (four offspring) 0.0394 0.00523 0.00108
80 trios, 240 unrelated 0.00925 0.00195 0.000554
SNPs with 80 nuclear families (twooffspring) , 160 unrelated 0.00889 0.00166 0.000458
maf < 5% 80 nuclear families (three offspring), 80 unrelated 0.00842 0.00145 0.00036
80 nuclear families (four offspring) 0.00793 0.00114 0.000263
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Table 7: Genotype discordance rate of heterozygous calls (Simulation II)
Depth 5 5 10 10 20 20 30 30
Method GATK FLDC GATK FLDC GATK FLDC GATK FLDC
F3 0.164 0.0092 0.0277 0.0042 0.00454 0.0026 0.00313 0.00256
F4 0.164 0.0084 0.0277 0.0037 0.00454 0.0025 0.00313 0.00255
F5 0.164 0.0077 0.0277 0.0032 0.00454 0.0024 0.00313 0.00253
F6 0.1638 0.0086 0.0276 0.0037 0.00453 0.0024 0.00312 0.00250
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Figure 13: Phasing error rate (Simulation I). C1: trios; C2: nuclear families of two
offspring; C3: nuclear families of three offspring and C4: nuclear families of four offspring.
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Table 8: Phasing error rate (Simulation I)
2x 6x 10x
80 trios, 240 unrelated 2e-05 1.37e-05 1.09e-05
BE = 20 80 nuclear families (twooffspring) , 160 unrelated 1.72e-05 9.27e-06 6.68e-06
80 nuclear families (three offspring), 80 unrelated 1.53e-05 5.45e-06 3.36e-06
80 nuclear families (four offspring) 1.4e-05 2.8e-06 7.22e-07
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Figure 14: Mendelian error (Simulation I). C1: trios; C2: nuclear families of two
offspring; C3: nuclear families of three offspring and C4: nuclear families of four offspring.
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Table 9: Mendelian error (Simulation I)
2x 6x 10x
80 trios, 240 unrelated 13.86 3.737 1.422
BE = 20 80 nuclear families (twooffspring) , 160 unrelated 13.06 3.422 1.142
80 nuclear families (three offspring), 80 unrelated 11.23 2.946 0.8898
80 nuclear families (four offspring) 9.035 2.366 0.6297
Table 10: Mendelian error (Simulation II)
Depth 5 5 10 10 20 20 30 30
Method GATK FLDC GATK FLDC GATK FLDC GATK FLDC
F3 28212.6 1118.1 6475.1 483.27 927.267 182.2 628.2 163.5
F4 28212.6 962.2 6475.1 350.13 927.267 134.6 628.2 126.3
F5 28212.6 718.3 6475.1 227.73 927.267 93.87 628.2 86.1
F6 33427 350.6 7420.6 99.3 1161.2 46 804.5 39.1
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Figure 15: Genotype discordance rate of heterozygous calls (Simulation III).
ref10: 10 founders; ref20: 20 founders; ref40: 40 founders and ref60: 60 founders.
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Table 11: Genotype discordance rate of heterozygous calls (Simulation III)
reference (# of founders) 10 20 40 60
BE = 20 2x 0.071 0.0406 0.0281 0.0246
2 trios 6x 0.0195 0.0104 0.0068 0.00549
10x 0.00555 0.00297 0.00204 0.00187
BE = 20 2x 0.0658 0.0384 0.0279 0.0248
3 trios 6x 0.0204 0.0114 0.00736 0.00556
10x 0.00544 0.00306 0.00205 0.00189
BE = 20 2x 0.0646 0.0383 0.0272 0.0239
4 trios 6x 0.0189 0.0117 0.0072 0.00578
10x 0.005 0.00285 0.00199 0.00168
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Figure 16: Phasing error rate (Simulation III). ref10: 10 founders; ref20: 20 founders;
ref40: 40 founders and ref60: 60 founders.
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Table 12: Phasing error rate (Simulation III)
reference (# of founders) 10 20 40 60
BE = 20 2x 0.00234 0.00121 0.000852 0.000702
2 trios 6x 0.00254 0.000917 0.000485 0.000372
10x 0.00174 0.000506 0.000373 0.000194
BE = 20 2x 0.00138 0.000725 0.000536 0.000455
3 trios 6x 0.00149 0.000631 0.000333 0.000212
10x 0.00109 0.000218 0.000152 0.000119
BE = 20 2x 0.0011 0.000569 0.000413 0.000312
4 trios 6x 0.00101 0.000461 0.000251 0.000194
10x 0.00071 0.000142 0.00011 7.43e-05
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Figure 17: Mendelian error (Simulation III). ref10: 10 founders; ref20: 20 founders;
ref40: 40 founders and ref60: 60 founders.
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Table 13: Mendelian error (Simulation III)
reference (# of founders) 10 20 40 60
BE = 20 2x 5.917 3.208 1.917 1.458
2 trios 6x 2.208 1 0.75 0.4167
10x 0.1667 0.3333 0.1667 0.04167
BE = 20 2x 5.611 2.889 1.667 1.583
3 trios 6x 2.139 1.083 0.7222 0.5833
10x 0.3333 0.1944 0.1389 0.2222
BE = 20 2x 5.229 3.042 1.708 1.5
4 trios 6x 1.604 1.521 0.7083 0.4792
10x 0.2292 0.1042 0.1875 0.2083
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5.0 CONCLUSIONS AND FUTURE DIRECTIONS
5.1 SUMMARY OF CONTRIBUTIONS
In chapter 2, we provided a practical guideline for users to choose the most appropriate
meta-analysis method when combining microarray data sets. For instance, if we are looking
at the study-specific markers (e.g. microarray data sets with different tissues target on
same disease trait, which means we expected “heterogeniety” between studies), the meta-
analysis methods target on HSB (DE genes has non-zero effect size in “one or more” studies)
can identify tissue-specific DE genes. Among the meta-analysis methods target on HSB we
compared in this project, we will suggest to use adaptive weighted (AW) Fisher’s method
because this method provides an additional information of adaptive weight index (0: non-
significant or 1: significant) and its performance is comparable to Fisher’s and Stouffer’s
methods (see Table 2). When there is no prior information can be obtained, one can also
uses our proposed entropy measure to understand the data structure (see Figure 7 (b)).
In addition, HSA or HSr-typed meta-analysis methods are more appropriate to detected
conserved and consistent DE genes across all studies.
In chapter 3, we developed a meta-clustering method to identified modules consistently
co-expressed in all 11 transcriptomic MDD studies. Around 7,500 genes (we filtered out 25%
scattered genes) were clustered into 50 co-expressed modules, and integrated with external
databases, such as pathway database (MSigDB) and catalog of GWAS database (see overall
analytical strategy in Figure 8). One robust module with 88 genes was significantly enriched
in eight lists of genetic markers located nearby genes associated with major depression and
related phenotype such as neuropsychiatric disorders; brain or neurological functions; disease
sharing clinical risk with MDD (Diabetes, Hypertension, etc) (more detail was described in
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section 3.2.5 and Figure 9). In pathway analysis, these 88 genes was enriched in GABA
or Gultamate-related pathways, which may share the similar biological function of brain
(more detail was described in sections of 3.2.7, 3.3.4 and Table 5). We also showed that our
meta-analyzed co-expression modules can achieve more accurate and robust gene modules
(see section 3.3.5 and Figure 10).
In chapter 4, we proposed a computationally efficient algorithm and developed a software
“FamLDCaller” to call genotypes of next generation sequencing (NGS) data sets incorpo-
rated by family structures of nuclear family (multiple offspring) or complex family (more
than two generations) (Objective 1). We showed that we can achieve more accurate geno-
type calls and reduced the Mendelian and phasing errors by adding more offspring in each
family from the results of simulation studies and real data analysis, especially with low cov-
erage data sets. In addition, Our proposed software “FamLDCaller” includes a function to
incorporate samples from reference panels such as 1,000 Genome Project to call genotypes of
family-structured NGS data sets with small sample sizes (Objective 2). We concluded more
accurate genotypes can be achieved when incorporating more references.
In conclusion, the thesis first performed a comprehensive comparative study of twelve mi-
coarray meta-analysis methods, which can be categorized according to three types of hypoth-
esis settings they best tested (see simulation result in section 2.3.2) and we provided an appli-
cation guideline for practitioners based on our proposed four quantitative evaluation criteria
applied in six real examples (see discussion in section 2.4.1). Second, the thesis then presented
a meta-clustering method to combine 11 MDD microarray studies to construct conserved co-
expressed modules incorporated by GWAS result and pathway databases. Third, we devel-
oped a software “FamLDCaller” (http://genome.sph.umich.edu/wiki/FamLDCaller) which
can be analyzed (1) in NGS data set with family structures of nuclear or complex families;
(2) in NGS data set with small sample sizes incorporated by publicly available reference
panels from 1,000 Genome Project. Taken together, this thesis provides several advantages
of integrative analysis of omics data: (1) good summary of meta-analysis methods of mi-
croarray studies; (2) the needs of meta-clustering method to generate robust co-expressed
modules and further integrate with GWAS and pathway databases; (3) Genotype callings
method integrating family structure.
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5.2 FUTURE DIRECTIONS
Below I will briefly discuss possible future direction from this thesis.
5.2.1 Consistency of differential expression (DE) changes in Adaptive weighted
Fisher
In chapter 2, only Stouffer’s method (belongs to HSB) and REM (belongs to HSr) methods
can avoid detecting markers with discordance effect sizes when combining multiple microar-
ray studies from the simulation study target on the case discordance effect sizes (see simula-
tion result in section 2.3.2 and Figure S3). However, Stouffer’s method became unstable as
number of studies increased and is too sensitive to extremely small p-values in few studies;
REM method is not robust enough to detect all the concordance markers. As a result, most
developed meta-analysis methods were not designed to handle the case of discordance effect
sizes, which is a common issue in real applications. In order to detect concordant DE genes,
we can simply perform a post hoc filtering procedure by removing any detected biomarkers
with discordant directions based on significant studies defined by adaptive weight Fisher’s
method (only check studies with “1” from the adaptive weighted vector w∗, see how w∗ was
generated from AW Fisher’s method in section 2.2.3). Alternatively, we may modify the
hypothesis setting and define a new concordant-based AW statistic. We expect the later
approach will perform better and will be our future direction.
5.2.2 MetaClustering-clusters
In chapter 3, we applied the meta-clustering method “PPAM” by taking the mean of dissim-
ilarity measure matrix (dissimilarity measure between gene i and gene j for a given single
study k was defined by d
(k)
i,j = 1− |cor(Xik, Xjk)|, where cor(Xik, Xjk) is the Pearson corre-
lation of the two gene vectors.) from K (K = 11) MDD transcriptome studies (see Figure
18 (A): MetaClustering-Distances). Here we aim at detecting conserved co-expressed pat-
tern in most or all studies. There is an alternative way to perform meta-clustering method
at clusters level in co-expression analysis. We can apply clustering method to each single
86
study separately and combine the clustering results in the following step (see Figure 18 (B):
MetaClustering-Clusters). Here we will combine the clustering results constructed from each
studies, hence my proposed future direction will aim at detecting co-expressed gene modules
in “majority” of studies.
5.2.3 Allowing for non-autosomal genotype calling and short indels
Trio-based genotype calling method proposed by Chen et al. [2013], our developed method
“FamLDCaller” can not only handles nuclear or complex family structures, but also and
allows people to use external database (e.x. 1,000 Genome Project) as reference panels
to obtain more accurate genotype calls when analyzing family-structured NGS data sets
with small sample sizes. In the future, our method can be modified to handle X and Y
chromosomes. For males, the model can be reformulated to handle a haploid case where
each hidden state is one haplotype rather than a pair. In the same principle, for females, we
can calculate P (Ri|Si), where Si = (Si,f , Si,m), Si,f is a pair of reference haplotype and Si,m
is a reference haplotype. The transmission and emission probabilities need to be modified
accordingly. In addition, although our methods focus on SNPs and haplotypes, they can
be modified to accommodate short insertions or deletions by reconstructing P (Gi|Si) and
P (Ri|Gi), to include a modified error model and the information about read depth.
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Figure 18: General workflow of meta-clustering methods to combine co-
expressed genes in different approaches. A. Meta-clustering Distance; B. Meta-
clustering Clusters. “This Figure is used with permission by Rui Chen’s in his Doctoral
Thesis proposal proposed in 2014”
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     APPENDIX: SUPPLEMENTARY FIGURES AND TABLES
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Figure S1: Meta QC.
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Figure S2: Heatmap of simulated example (red color represents up-regulated
genes).
91
maxP (HSA)
# of DE studies
Fr
eq
ue
nc
y
0 2 4
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
rOP (HSr)
0 1 2 3 4 5
0
50
10
0
15
0
20
0
0
50
10
0
15
0
20
0
0
50
10
0
15
0
20
0
minP (HSB)
# of DE studies
Fr
eq
ue
nc
y
0 1 2 3 4 5
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fisher (HSB)
# of DE studies
Fr
eq
ue
nc
y
0 1 2 3 4 5
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Underlying Truth
# of DE studies
Fr
eq
ue
nc
y
0 1 2 3 4 5
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
AW (HSB)
# of DE studies
Fr
eq
ue
nc
y
0 2 4
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Stouffer (HSB)
# of DE studies
Fr
eq
ue
nc
y
0 1 2 3 4 5
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
PR (HSA)
# of DE studies
Fr
eq
ue
nc
y
0 1 2 3 4 5
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
SR (HSA)
# of DE studies
Fr
eq
ue
nc
y
0 1 2 3 4 5
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
FEM (HSB)
# of DE studies
Fr
eq
ue
nc
y
0 2 4
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
REM (HSr)
# of DE studies
Fr
eq
ue
nc
y
0 1 2 3 4 5
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
RankProd (HSB)
# of DE studies
Fr
eq
ue
nc
y
0 1 2 3 4 5
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
RankSum (HSB)
# of DE studies
Fr
eq
ue
nc
y
0 1 2 3 4 5
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Fr
eq
ue
nc
y
0
50
10
0
15
0
20
0
Figure S3: The histograms of the true number of DE studies among detected
DE genes under FDR=5% in each method for discordance case (green color rep-
resents all concordance effect sizes; blue color represents one study has opposite
effect size and red color represents two studies have opposite effect size).
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Figure S4: Cumulative moving average to determine D = 100.
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Figure S5: The ROC curves and AUC for the hypothesis settings of HSA-type
and (red line) HSB-type (black line) in each meta-analysis method.
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Figure S6: Multidimensional scaling (MDS) plots of individual data sets.
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Figure S7: Stability and Robustness plot for α = 0.0001, 0.005 and 0.01.
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Figure S8: Diagram of pre-processing procedure of 11 MDD transcriptome data
sets.
Number of samples and number of matched genes in each single (MDD) study. In matching
step, we allowed 20% missing studies, then 16,443 genes were identically matched among
11 studies. 13,500 genes were kept by filtering out lower sum ranks of median row means;
10,000 genes were kept by filtering out lower sum ranks of median row standard deviations.
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Figure S9: Pedigree of complex family simulated from 1,000 genome project.
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Table S1: Detailed data sets description
Author Year Platform Sample Size Source
(Case/Controls)
Welsh 2001 HG-U95A 34(25/9) public.gnf.org/cancer/
Prostate Cancer Singh 2002 HG-U95Av2 102(52/50) www.broad.mit.edu
Studies Lapointe 2004 cDNA 103(62/41) GSE3933
(Normal v.s Yu 2004 HG-U95Av2 83(65/18) GSE6919
Primary) Varambally 2005 HG-U133 Plus 2 13(7/6) GSE3325
Wallace 2008 HG-U133A2 89(69/20) GSE6956
Nanni 2006 HG-U133A 30(23/7) GSE3868
Prostate Cancer Lapointe 2004 cDNA 71(62/9) GSE3933
Studies Varambally 2005 HG-U133 Plus 2 13(7/6) GSE3325
(Primary v.s Yu 2004 HG-U95Av2 90(65/25) GSE6919
Metastasis Tomlins 2006 cDNA 49(30/19) GSE6099
Freije 2004 HG-U133A,B 85(59/26) GSE4412
Phillips 2006 HG-U133A,B 100(76/24) GSE4271
Brain Cancer Sun 2006 HG-U133 Plus 2 100(81/19) GSE4290
Studies Petalidis 2008 HG-U133A 58(39/19) GSE1993
Gravendeel 2009 HG-U133 Plus 2 175(159/16) GSE16011
Paugh 2010 HG-U133 Plus 2 42(33/9) GSE19578
Yamanaka 2006 Agilent 29(22/7) GSE4381
MD1 AMY 2009 HG-U133 Plus 2 28(14/14) Dr. Sibille
MD1 ACC 2009 HG-U133 Plus 2 32(16/16) Dr. Sibille
MD3 ACC 2009 HumanHT-12 44(22/22) Dr. Sibille
MDD Studies MD2 ACC M 2010 HG-U133 Plus 2 18(9/9) Dr. Sibille
MD2 ACC F 2010 HG-U133 Plus 2 26(13/13) Dr. Sibille
MD2 DLPFC M 2010 HG-U133 Plus 2 28(14/14) Dr. Sibille
MD2 DLPFC F 2010 HG-U133 Plus 2 32(16/16) Dr. Sibille
MD3 AMY 2009 HumanHT-12 42(21/21) Dr. Sibille
Pardo 2005 Codelink 24(13/11) GSE2052
Yang 2007 Agilent 43K 29(20/9) GSE5774
Vuga 2009 Codelink 7(4/3) GSE10921
Lung Disease Konishi 2009 Agilent 4x44K 38(23/15) GSE10667
Studies (IPF) KangA 2011 Agilent 4x44K 63(52/11) Dr. Kaminski
KangB 2011 Agilent 8x60K 96(75/21) Dr. Kaminski
Larsson 2008 HG-U133 Plus 2 12(6/6) GSE11196
Emblom 2010 cDNA 58(38/20) GSE17978
Loi 2007 HG-U133A 125 GSE6532
Miller 2005 HG-U133A,B 236 GSE3494
Pawitan 2005 HG-U133A,B 159 GSE1456
Breast Cancer Sotiriou2006 2006 HG-U133A 187 GSE2990
Studies Desmedt 2007 HG-U133A 198 GSE7390
Wang 2005 HG-U133A 286 GSE2034
Sotiriou2003 2003 cDNA 110
vantVeer 2002 cDNA 97
99
Table S2: MetaQC results
Data set Study IQC EQC CQCg CQCp AQCg AQCp Rank
1. Welsh 4.38 0.53* 54.63 64.08 18.9 39.09 2.25
2. Yu 6.64 0.9* 46.91 55.48 14.84 26.2 2.33
Prostate Cancer 3. Lapointe 2.1* 1.33* 27 53.98 6.28 18.29 3.17
Studies (Normal 4. Singh 1.14* 0.95* 14.67 19.21 3.85 18.34 4.17
v.s Primary) 5. Varambally 4.38 1.06* 8.7 3.29 2.55 2.41 4.92
6. Wallace 7.86 0.27* 0* 27.05 0* 3.69 5.33
7. Nanni 0.75* 0.7* 0.88* 4.2 0.63* 11.45 5.83
Prostate Cancer 1. Varambally 6.4 0.27* 16.88 23.86 5.5 11.66 1.5
Studies (Primary 2. Yu 4.74 0.94* 6.77 13.73 1.43* 6.4 2
v.s Metastasis) 3. Lapointe 3.3 0.8* 2.91 4.08 2.95 5.95 2.67
4. Tomlins 1.3* 0.51* 0.21* 0.21* 0.1* 0.41* 3.83
1. Sun 4.96 2.64 151.63 128.5 61.12 48.82 1.5
2. Petalidis 4.24 1.17* 148.97 122.39 56.74 75.83 2.83
Brain Cancer 3. Freije 5.27 2.52 89.34 68.09 43.31 20.49 3
Studies 4. Phillips 4.81 1.73* 84.93 56 37.22 25.31 3.83
5. Gravendeel 6.27 1.13* 38.53 48.98 11.9 35.74 4.17
6. Paugh 1.51* 1.26* 1.62* 0.17* 1.7* 1.77* 6
7. Yamanaka 0.1* 0.56* 0.92* 0.94* 1.85* 0.31* 6.67
1. MD2 ACC F 8.48 1.08* 34.48 54.49 11.9 10.6 1.83
2. MD2 DLPFC F 7.87 1.13* 34.58 32.29 6.33 6.91 2.67
3. MD2 DLPFC M 2.55 2.08* 24.36 46.97 3.54 20.54 3
MDD Studies 4. MD1 ACC M 5.03 0.45* 23.25 50.38 4.29 10.74 3.67
5. MD3 ACC F 0.74* 1.05* 9.33 9.31 4.8 4.62 5.5
6. MD2 ACC M 2.99 1.04* 7.41 9.4 3.36 0.96* 5.83
7. MD1 AMY M 1.97* 0.11* 5.47 23.76 1.93* 7.83 6.17
8. MD3 AMY F 1.56* 0.96* 0.96* 0.15* 0.38* 2.31 7.33
1. KangA 6.64 0.34* 140.41 85.47 39.01 40.71 2.17
2. KangB 5.46 0.64* 94.08 45.06 27.4 22.56 2.33
3. Konishi 6.76 0.77* 17.99 31.45 5.99 21.42 3
Lung Disease 4. Yang 4.07 0.44* 26.61 23.7 9.57 18.41 4.17
Studies (IPF) 5. Pardo 4.44 0.35* 15.6 29.98 14.56 17.09 4.5
6. Vuga 2.28 0.39* 1.41* 17.32 1.02* 14.5 6
7. Larsson 1.85* 1.32* 0.54* 4.83 0.12* 1.26* 6.33
8. Emblom 0.03* 0.19* 1.68* 0.07* 0.68* 0.56* 7.5
1. Pawitan 3.63 4 29.79 116.82 21.99 83.85 2.25
2. Loi 6.64 4 13.9 66.34 7.32 62.05 2.58
3. Sotiriou2006 1.3* 0.38* 49.91 134.6 14.3 72.17 3.33
Breast Cancer 4. Miller 6.14 4 7.64 47.17 4.24 30.76 3.58
Studies 5. Desmedt 6.26 4 5.09 14.94 3.24 17.21 4.42
6. Wang 6.03 3.52 0.75* 25.72 2.48 26.01 5.17
7. Sotiriou2003 2.15* 1.37* 0.28* 4.62 0.07* 2.58 6.83
8. vantVeer 0.03* 0.26* 0.14* 1.83* 0.15* 0.8* 7.83
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Table S3: Data sets and number of matched genes
Disease # of studies # of studies Comparison # of matched
passed MetaQC genes
Prostate cancer 7 6 Binary 6,940
(normal vs. primary)
Prostate cancer 4 3 Binary 4,260
(primary vs. metastastasis)
Brain cancer 7 5 Binary (AA vs. GBM) 6,019
(AA vs. GBM)
Major Deoressive 8 6 Binary 6,000
Disorder (MDD) (Normal vs. MDD)
Idiopathic Pulmonary 8 6 Binary 5,481
Fibrosis (IPF) (Normal vs. IPF)
Breast cancer 8 6 Survival time 10,688
(Relapse free survival)
Based on the QC, the study ”Nanni” was removed from 7 prostate cancer studies comparing
normal and primary cancer patients; the study ”Tomlins” was removed from 4 prostate cancer
studies com-paring primary cancer patients and metastasis cancer patients. In the 7 brain
cancer studies, the ”Paugh” and ”Yamanaka” studies were removed. In the case of major
depression disorder (MDD) studies, we removed the study ”MD3 AMY F”. Studies ”Larsson”
and ”Em-blom” were removed from 8 lung disease studies. In breast cancer survival data sets,
two cDNA data sets ”Sotiriou2003” and ”vantVeer” were removed.
Table S4: Mean standardized rank (MSR) and aggregated standardized rank (ASR) for
detection capability
Fisher AW StoufferminPFEMRankSsumrOPRankProdmaxPREM SR PR
Prostate cancer (normal v.s. primary) 0.08 0.17 0.25 0.34 0.42 0.51 0.63 0.61 0.78 0.80 0.980.93
Prostate cancer (primary v.s. metastasis) 0.08 0.17 0.25 0.33 0.55 0.45 0.51 0.71 0.70 0.83 0.921.00
Brain cancer (AA v.s. GBM) 0.08 0.17 0.27 0.40 0.40 0.54 0.57 0.65 0.75 0.75 0.921.00
MDD 0.17 0.22 0.26 0.51 0.55 0.48 0.49 0.52 0.72 0.83 0.850.90
IPF 0.08 0.17 0.27 0.32 0.42 0.49 0.67 0.60 0.81 0.76 0.970.95
Breast Cancer 0.13 0.33 0.41 0.38 NA NA 0.63 NA 0.75 NA 0.990.89
Aggregated standardized ranks 0.11 0.20 0.29 0.38 0.47 0.49 0.58 0.62 0.75 0.79 0.940.95
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Table S5: Mean standardized rank (MSR) and aggregated standardized rank (ASR) for
biological association
StoufferFisher AW PR rOP SR minPRankProdFEMmaxPREMRankSum
Prostate cancer (normal v.s. primary) 0.42 0.38 0.380.41 0.44 0.53 0.49 0.58 0.63 0.69 0.75 0.80
Prostate cancer (primary v.s. metastasis) 0.36 0.38 0.390.42 0.36 0.52 0.49 0.55 0.68 0.72 0.78 0.86
Brain cancer (AA v.s. GBM) 0.44 0.45 0.400.54 0.42 0.64 0.47 0.50 0.56 0.65 0.72 0.73
MDD 0.27 0.29 0.400.28 0.42 0.28 0.56 0.68 0.80 0.84 0.81 0.88
IPF 0.35 0.41 0.360.40 0.45 0.48 0.52 0.63 0.66 0.72 0.76 0.78
Breast Cancer 0.45 0.45 0.480.42 0.52 0.56 0.71 NA NA 0.92 NA NA
Aggregated standardized ranks 0.38 0.39 0.400.41 0.43 0.50 0.54 0.59 0.67 0.75 0.76 0.81
Table S6: Mean standardized rank (MSR) and aggregated standardized rank (ASR) for
stability
RankProdRankSumFisher PR REM AW minPStouffer SR rOPFEMmaxP
Prostate cancer (normal v.s. primary) 0.08 0.17 0.40 0.38 0.27 0.46 0.70 0.72 0.71 0.92 0.70 1.00
Prostate cancer (primary v.s. metastasis) 0.08 0.17 0.38 0.43 0.35 0.39 0.58 0.66 0.73 0.84 0.90 1.00
Brain cancer (AA v.s. GBM) 0.08 0.17 0.37 0.40 0.30 0.50 0.74 0.68 0.77 0.67 0.83 1.00
MDD 0.04 0.04 0.23 0.19 0.82 0.45 0.45 0.58 0.36 0.67 0.78 0.90
IPF 0.08 0.17 0.38 0.44 0.32 0.52 0.49 0.61 0.76 0.92 0.82 1.00
Breast Cancer NA NA 0.18 0.32 NA 0.50 0.51 0.59 0.70 0.80 NA 0.89
Aggregated standardized ranks 0.07 0.14 0.32 0.36 0.41 0.47 0.58 0.64 0.67 0.80 0.81 0.97
Table S7: Mean standardized rank (MSR) and aggregated standardized rank (ASR) for
robustness
minP AW FisherStoufferRankProd PR SR REMFEMrOPmaxPRankSum
Prostate cancer (normal v.s. primary) 0.20 0.27 0.23 0.34 0.56 0.520.54 0.59 0.65 0.80 0.79 1.00
Prostate cancer (primary v.s. metastasis) 0.17 0.21 0.24 0.33 0.47 0.530.65 0.65 0.70 0.81 0.79 0.94
Brain cancer (AA v.s. GBM) 0.24 0.29 0.31 0.40 0.52 0.540.59 0.63 0.57 0.76 0.71 0.94
MDD 0.55 0.51 0.56 0.59 0.33 0.470.37 0.55 0.52 0.49 0.58 0.97
IPF 0.21 0.31 0.29 0.35 0.47 0.490.62 0.51 0.74 0.76 0.73 1.00
Breast Cancer 0.57 0.60 0.62 0.51 NA 0.490.62 NA NA 0.40 0.70 NA
Aggregated standardized ranks 0.32 0.37 0.37 0.42 0.47 0.510.57 0.59 0.64 0.67 0.72 0.97
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Table S8: Meta modules and GWAS gene lists(cases and controls)
Cluster # of genes Neuroticism MDD2000+ Mega MDD Mega bipolar MDD
Neuropsychiatric
Neurological
Medical
Disorder
disorders
illnesses
and brain
sharing
phenotypes
clinical risk
with MDD
1 94 1.0000 1.0000 1.0000 0.9055 0.4510 0.8924 0.8395 0.8220
2 114 1.0000 0.2349 1.0000 0.9529 1.0000 0.2977 0.3431 0.7862
3 187 1.0000 0.1919 0.4421 0.3674 0.5863 0.3231 0.1025 0.0138
4 165 0.1287 0.1483 1.0000 0.3726 0.5012 0.1193 0.0206 0.2418
5 132 0.2638 1.0000 0.0616 0.1788 0.1648 0.2689 0.2783 0.0085
6 118 0.2244 0.2469 1.0000 0.3611 0.5722 0.1871 0.2630 0.0997
7 203 0.0183 1.0000 1.0000 0.6054 0.0016 0.0147 0.0086 0.0925
8 233 0.0991 0.4377 1.0000 0.0160 0.5230 0.4444 0.8360 0.0448
9 130 0.2581 1.0000 1.0000 0.7913 1.0000 0.7638 0.9700 0.5708
10 161 0.7094 1.0000 0.0870 0.1290 0.7387 0.4564 0.6628 0.2194
11 215 1.0000 1.0000 1.0000 0.5324 0.6805 0.3474 0.5406 0.3031
12 251 0.0406 0.4572 0.1799 0.4642 0.2199 0.1237 0.0533 0.3904
13 94 1.0000 0.5357 1.0000 0.0152 0.7858 0.5150 0.4018 0.8220
103
14 369 0.5340 0.5419 0.6882 0.7633 0.7186 0.8008 0.8453 0.8263
15 146 0.6735 1.0000 1.0000 0.9446 0.2104 0.5232 0.1982 0.6833
16 154 0.3256 1.0000 1.0000 0.4530 0.4555 0.7367 0.6037 0.9340
17 85 0.4775 1.0000 1.0000 0.4685 0.4008 0.4368 0.6153 0.2051
18 32 1.0000 1.0000 1.0000 0.1441 1.0000 1.0000 0.7005 0.0600
19 204 1.0000 0.6810 0.4713 0.8537 0.8469 0.7052 0.5611 0.9968
20 109 0.5656 0.0577 0.2871 0.6651 0.2581 0.2634 0.1874 0.5807
21 263 0.5969 0.7250 1.0000 0.9644 0.1331 0.3495 0.6833 0.3448
22 53 1.0000 1.0000 0.1512 0.6498 0.2110 0.6272 1.0000 0.9213
23 189 0.4209 1.0000 1.0000 0.9863 0.8148 0.9823 0.9754 0.9793
24 97 1.0000 1.0000 0.2598 0.9837 0.2066 0.3399 0.5916 0.2994
25 68 1.0000 1.0000 1.0000 0.7781 1.0000 1.0000 0.9671 0.8335
26 293 0.8965 1.0000 1.0000 0.5548 0.5155 0.2725 0.3434 0.3939
27 126 1.0000 1.0000 1.0000 0.7707 0.6082 0.5633 0.7316 0.3741
28 181 0.7512 0.6583 0.1061 0.4739 0.3356 0.5812 0.5972 0.3378
29 131 0.6334 1.0000 1.0000 0.9744 0.0607 0.4185 0.5165 0.5784
30 231 0.5258 1.0000 1.0000 0.3574 0.9781 0.9838 0.0930 0.6435
31 224 0.5092 0.1067 1.0000 0.2154 0.1542 0.1782 0.1621 0.3536
32 178 1.0000 0.6557 0.4260 0.7507 0.9468 0.5633 0.2519 0.0726
33 117 1.0000 1.0000 1.0000 0.8679 0.8535 0.8488 0.9786 0.9964
34 236 0.8380 1.0000 0.5223 0.8624 0.7401 0.2262 0.5955 0.8679
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35 88 0.0287 0.0339 0.0001 0.0284 0.0537 0.0078 0.0293 0.0524
36 149 0.6810 1.0000 1.0000 0.4190 0.9138 0.8481 0.6814 0.9228
37 156 0.3312 1.0000 1.0000 0.0277 0.9233 0.8721 0.1851 0.3050
38 122 0.6070 1.0000 0.0536 0.9645 0.8651 0.5343 0.5629 0.3433
39 91 1.0000 0.5241 1.0000 0.0041 1.0000 0.9753 0.9930 0.9874
40 142 0.6633 0.3189 1.0000 0.9373 0.6731 0.6692 0.4926 0.4969
41 192 0.7716 1.0000 1.0000 0.0542 0.6043 0.2308 0.3575 0.4075
42 113 1.0000 1.0000 1.0000 0.9512 1.0000 0.9900 0.9922 0.9714
43 114 0.5820 0.2349 0.2981 0.6992 1.0000 0.9904 0.9343 0.7862
44 186 1.0000 1.0000 1.0000 0.5050 0.8077 0.7529 0.9428 0.9934
45 112 0.5755 1.0000 1.0000 0.3167 0.8409 0.6540 0.3230 0.6051
46 198 1.0000 1.0000 0.4611 0.5769 0.6253 0.3853 0.0378 0.9066
47 167 1.0000 0.1521 1.0000 0.6939 0.5093 0.7979 0.8841 0.6691
48 148 0.6786 0.3368 1.0000 0.9863 0.6951 0.8444 0.9883 0.5413
49 119 0.5978 0.6220 1.0000 0.7307 1.0000 0.9922 0.9990 0.9776
50 117 0.2216 1.0000 1.0000 0.5338 0.5676 0.8488 0.8777 0.9964
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